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ABSTRACT
INVESTIGATING A NOVEL FUNCTION FOR PHOSPHOSERINE AMINOTRANSFERASE 1
(PSAT1) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-MEDIATED LUNG
TUMORIGENESIS
Rumeysa Biyik-Sit
March 18, 2021

Phosphoserine aminotransferase 1 (PSAT1) catalyzes the second enzymatic step within
the serine synthetic pathway (SSP) and its expression is elevated in numerous human cancers,
including non-small cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) mutant
NSCLC is characterized by activating mutations within its tyrosine kinase domain and accounts for
17% of lung adenocarcinomas. Although elevated SSP activity has been observed in EGFR-mutant
lung cancer cells, the involvement of PSAT1 in EGFR-mediated oncogenesis is still unclear.
Here, we explore a putative non-canonical function for PSAT1 using biochemical
approaches to elucidate unknown interacting proteins and genomic RNA-seq profiling to identify
cellular processes impacted by PSAT1. We further determined the cellular phenotypes affected by
PSAT1 loss, which were verified by experimental rescue studies, including metabolite
supplementation and restoration of protein expression/localization.
Initially, we identified PKM2 as a novel PSAT1 associating protein. Although PSAT1
selectively induced the pyruvate kinase (PK) activity of recombinant PKM2, its loss in NSCLC cells
did not alter cellular PK activity or expression of PKM2. However, fractionation studies revealed
that PSAT1 localized to the nucleus and was required for EGFR-mediated nuclear PKM2
translocation. Phenotypically, PSAT1 loss led to a defect in EGFR-activated cell motility, which was
partially restored by a nuclear expression of an acetyl-mimetic PKM2 mutant, but not wild-type
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PKM2 or metabolite supplementation. To get insight into cellular mechanisms downstream of
PSAT1 activity, we conducted RNA-seq profiling. Consistent with the reported function of PSAT1,
E2F targets and nucleotide metabolism genes were decreased upon PSAT1 silencing. Accordingly,
the anchorage-independent growth was impacted by PSAT1 silencing and rescued by metabolite
supplementation, but not by nuclear PKM2 expression. The correlation between decreased
expression of actin-related genes and F-actin formation upon PSAT1 silencing suggested a role for
PSAT1 in actin cytoskeleton rearrangements. Furthermore, identified PSAT1-associated gene
signatures were predictive towards survival outcomes in EGFR-mutant NSCLC. Together, our data
suggest multiple roles for PSAT1 in promoting EGFR-mutant NSCLC involving not only canonical
SSP activity but also a non-canonical nuclear function through mediating protein localization. These
findings have laid the foundation for future studies to fully define PSAT1’s response under EGFRactivation.
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CHAPTER 1
INTRODUCTION
Tumor cells require metabolic reprogramming to fulfill the high energy demand and
macromolecule synthesis necessary for tumor growth. This also allows for cell survival under
unfavorable conditions, including nutrient deprivation and hypoxia, which are commonly found in
tumors (5, 6). Aerobic glycolysis, also known as the Warburg effect, is classically defined as
glycolytic metabolism to lactate even in the presence of oxygen (9). This was the earliest
demonstration of altered metabolism in cancer made by Otto Warburg in the 1920’s. Within this
phenomenon, tumor cells consume high amounts of glucose that allows for not only glycolytic ATP
production but also the production of the required biosynthetic precursors, such as nucleotides,
that stem from glycolytic metabolites. Although the importance of glucose metabolism has been
appreciated for some time, elucidation of changes within other metabolic pathways is an intense
area of study and a target for developing new anti-cancer drugs.
Recently, changes in serine metabolism have been a focus of extensive work due to its
role in the biosynthesis of many biological molecules, including nucleic acid synthesis, lipid
synthesis, and other amino acids (15, 16). In certain tumor cells, depletion of intracellular serine
through culture media manipulation leads to decreased cell proliferation, which can be rescued by
the addition of downstream metabolites (17, 18).

However, limiting extracellular serine may not

impact some types of tumors as they exhibit activated de novo serine biosynthesis (19). For
example, inhibition of the serine biosynthetic pathway by small-molecule antagonists suppresses
tumor cell proliferation even under serine proficient media, suggesting that activation of the serine
biosynthetic pathway may go beyond the requirement for general serine production for tumor
progression (20).
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In this introduction, we will discuss the contribution of serine metabolism to biosynthetic
pathways, cellular mechanisms leading to activation of serine biosynthesis, the cellular
consequences of pathway activation, and the importance of glycolytic enzyme function that
impinges on serine biosynthesis. Specifically, we will discuss the connection between glycolysis
and serine synthesis in non-small cell lung cancer (NSCLC) and review the reports investigating
the requirement of serine synthesis pathway (SSP) genes in lung cancer. As a substantial portion
of existing literature examines these metabolic changes in different subtypes of NSCLC, we will
provide a brief introduction about epidermal growth factor receptor (EGFR)-mutant lung cancer,
which comprises a significant percentage of NSCLC adenocarcinoma. Since phosphoserine
aminotransferase (PSAT1) catalyzes the second step in serine biosynthesis and is the focus of this
study, we will also review current reports related to its tumorigenic function. Lastly, we will highlight
recent reports implicating non-canonical functions for metabolic enzymes; specifically, those within
glycolytic, tricarboxylic acid (TCA) cycle, and serine synthetic pathways, all culminating with the
specific aims used to test the overall hypothesis of this work.
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Serine metabolism in cancer
Serine as a central donor for macromolecule synthesis
Serine functions as a central donor for many anabolic reactions that promote tumor growth
and survival (15, 28) (Fig. 1). Beyond the requirement for protein synthesis, cells can utilize serine
for the synthesis of other amino acids such as glycine and cysteine, which can then be used for the
production of glutathione for the maintenance of cellular redox homeostasis. Serine also contributes
to cell membrane formation via incorporation into sphingosine and phosphatidylserine.
In tumors, serine also impacts RNA/DNA synthesis through providing one-carbon units to
the folate cycle. 5,10-methylenetetrahydrofolate (CH2-THF), which is synthesized from
tetrahydrofolic acid (THF) methylation from the conversion of serine to glycine, contributes to
thymidine and purine synthesis (16, 28). Under serine starvation, cells convert glycine into serine
at the expense of one-carbon metabolism, which leads to inhibition of purine synthesis. This
underscores the importance of serine for cell proliferation. In addition to glutathione biosynthesis,
serine also promotes redox balance via nicotinamide adenine dinucleotide (NADH) synthesis within
the folate cycle (28).
Serine further contributes to S-adenyl-methionine (SAM) production within the methionine
cycle via its functional interaction with the folate cycle. Although the contribution of serine to
homocysteine’s re-methylation to methionine is controversial, serine is required for the de novo
biosynthesis of ATP. This is utilized for the adenylation of methionine, thereby highlighting a
putative requirement for SAM production (38). Furthermore, global decreases in DNA and histone
methylation upon serine depletion implicate cellular serine in maintaining the epigenetic landscape
of cells (38, 39).
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Figure 1. Serine contributes to many aspects of biomolecule synthesis.
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Contribution of serine biosynthesis to tumor progression
Serine is a non-essential amino acid that can be synthesized from the glycolytic
intermediate, 3-phosphoglycerate (3-PG) (Fig. 2). Phosphoglycerate dehydrogenase (PHGDH) is
the rate-limiting enzyme that catalyzes the first reaction of 3-PG and NAD+ to 3phosphohydroxypyruvate (3-PHP) and NADH. PSAT1 then transfers the amino group from
glutamate to 3-PHP to generate phosphoserine and α-ketoglutarate (α-KG). The final reaction in
the SSP pathway is the production of serine through dephosphorylation of phosphoserine by
phosphoserine phosphatase (PSPH) (28). Although serine is one of the most abundant amino
acids in the serum, many tumor types exhibit elevated serine biosynthetic activity. The importance
of serine in cellular biosynthesis and the elevated expression of the biosynthetic enzymes prompted
researchers to investigate a potential role for the SSP in tumorigenesis (15).
PHGDH amplification, frequently observed in melanoma and triple-negative breast cancer
(TNBC), accounts for the increased serine biosynthesis observed in these tumors (19, 40). While
this provides a growth advantage under serine-limiting conditions, it also makes them vulnerable
to PHGDH inhibitors (41). Stratification of NSCLC based on PHGDH expression found that
increased PHGDH correlates with elevation of downstream SSP genes and activity, supporting the
correlation between high PHGDH expression and serine biosynthesis (42). In addition, upregulation
of PHGDH and PSAT1 expression correlates with poor patient outcomes in various tumor types,
including NSCLC, colon, and estrogen receptor (ER) negative breast cancer (40, 43, 44).
It is obvious that activation of serine biosynthesis can provide a growth advantage to tumor
cells when serine is limiting. Yet, as serine is abundant in the serum, it is unclear why tumors exhibit
high SSP expression when they can readily obtain serine from the extracellular environment (15).
Inhibition of PHGDH activity via depletion or small-molecule inhibitors diminishes cell proliferation
in vitro and tumor growth in vivo (20, 45). Since NSCLC cells with high SSP activity produce more
RNA/DNA precursors, suppression of PHGDH leads to DNA damage, which can be partially
rescued by nucleoside addition (42). Another mechanistic study found a reduction in extracellular
13C-labeled

serine into AMP and dTMP in PHGDH inhibited cells (20). They found that inhibition of
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Figure 2. The schematic illustration of serine synthesis pathway (SSP) and
contribution to tumor metabolism. Pathway inhibition via siRNA gene targeting or
inhibitor impacts downstream metabolite production even in the presence of exogenous
serine. Supplementing SSP downstream metabolites can, in some cases, mitigate the
siRNA/inhibitor affect.
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serine synthesis leads to active cytosolic serine hydroxymethyl transferase 1 (SHMT1), which
“wastes” the one-carbon unit in order to regenerate serine from glycine at the expense of nucleotide
synthesis. Yet, depletion of SHMT1 restores the nucleotide production in SSP inhibited cells. This
strongly suggests that serine biosynthesis is necessary to promote the forward reaction in serineglycine one-carbon metabolism via suppressing SHMT1 activity.
Active serine synthesis has also been reported to be required for other pro-tumorigenic
processes. Serine production is necessary to maintain the epigenetic landscape in a Kras-activated
pancreatic cancer mouse model with loss of Lkb1 functions (46). Loss of Psat1-mediated SAM
production impacts DNA methylation, which is rescued by SAM addition. Further, elevated PHGDH
expression in EGFR-mutant NSCLC cells participates in erlotinib-resistance (47). While either
siRNA or pharmacological inhibition sensitizes resistant cells to erlotinib treatment via inducing
DNA damage, supplementation of the reactive oxygen species (ROS) scavenger, N-acetyl-cysteine
(NAC), is protective and indicates that serine biosynthesis may contribute to drug resistance
through redox balancing. Lastly, in addition to impacting downstream serine-derived metabolites,
SSP suppression also negatively impacts intermediary metabolism in tumors. As PSAT1 catalyzes
the conversion of glutamate to α-KG, it is an active player in glutamine anaplerosis in providing a
key TCA cycle intermediate. In TNBC cells, the SSP was found to contribute 50% of glutaminederived α-KG (40). In short, serine biosynthesis has been found to be crucial for efficient
biosynthetic reactions, glutamine anaplerosis, and tumor growth.
Regulators of SSP transcription
Increased gene expression of serine biosynthetic enzymes primarily accounts for the
activation of serine biosynthesis in tumors. Transcriptional regulation of SSP genes has been
observed under various conditions but is primarily induced by two main causes: oncogenic
activation and nutrient/oxidation stress (Fig. 3).
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A

B
Figure 3. Transcriptional regulation of SSP genes in cancer. A) Oncogenic activation:
(i) NRF2-ATF4; (ii) KDM4C-ATF4; (iii) G9A; (iv) EGFR mutant-ATF4; (v) MYCN-ATF4. B)
Stress-induced activation: (i) Serine starvation-GCN2-ATF4; (ii) nutrient stress
(Glucose/Glutamine/Serine-Glycine starvation)-c-MYC; (iii) Serine starvation/oxidative
stress/ inhibition of PKM2-MDM2-ATF4
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The analysis of serine biosynthesis activity using

13C-labeled

glucose metabolomics

coupled to transcriptomic analysis of a large panel of NSCLC tumors found that the transcription
factor nuclear factor erythroid-2-related factor 2 (NRF2) is an upstream regulator of SSP gene
expression (45). Silencing of NRF2 leads to down-regulation of SSP genes through decreased
activating transcription factor 4 (ATF4), as ATF4 restoration in NRF2 depleted cells rescues SSP
expression in NSCLC cells (Fig. 3A(i)). Lysine-specific demethylase 4C (KDM4C) functions as a
histone demethylase via removing methyl groups from the tri/di-methylated histone H3 lysine 9
(H3K9me3/2). Separately, the euchromatic histone-lysine N-methyltransferase 2 (EHMT2/G9A)
acts as monomethylase and accounts for the mono-methylation of H3K9. Both KDM4C and G9A
action results in the generation of a known epigenetic activation mark, H3K9me1, which leads to
transcriptional induction. KDM4C-mediated H3K9me1 at the ATF4 proximal promoter induces
ATF4 transcription (48). Subsequently, an ATF4-KDM4C interaction promotes SSP expression
(Fig. 3A(ii)). Another report demonstrated that G9A facilitates SSP gene expression via monomethylation of H3K9 at the promoter sites (Fig. 3A(iii)) (49). Although it remains unknown whether
KDM4C and G9A act together to promote SSP expression, the mechanism is not mutually
exclusive.
Investigation of the role of receptor tyrosine kinases in metabolic reprogramming has found
that activating mutations in EGFR lead to increased glucose-derived serine biosynthesis (Fig.
3A(iv)) (50). Bioinformatic analysis suggests both c-Myc and ATF4 as candidate transcription
factors responsible for EGFR-activated SSP transcription. However, siRNA loss of function studies
found activation of SSP expression was due to ATF4 and not c-MYC. Another study compared the
transcriptomic profiles of MYCN amplified neuroblastoma cells and non-amplified cells and
demonstrated elevated expression of SSP genes in MYCN amplified cells (51). Further functional
studies revealed that MYCN actually induces ATF4 expression via binding to the promoter region,
and subsequently, MYCN and ATF4 stimulate SSP transcription (Fig. 3A(v)). Taken together, these
reports demonstrate that SSP enzymes in cancer cells are elevated through various oncogenic
pathways, but induction of ATF4 expression seems a pre-requisite to promote SSP expression.
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In addition to oncogenic activation, limited nutrient availability and oxidative stress are able
to induce SSP expression in order to mediate the cellular stress response (Fig. 3B). Serine
starvation induces general control nonderepressible 2 (GCN2)-mediated translation of ATF4, which
as described above leads to ATF4-dependent SSP transcription (Fig. 3B(i)) (52). Simultaneously,
decreased pyruvate kinase activity in pyruvate kinase M2 (PKM2)-expressing cells results in
accumulation of the glycolytic intermediate 3-phosphoglycerate for serine biosynthesis. Also, the
mouse double minute 2 homolog (MDM2) can localize to the SSP promoter under oxidative stress,
serine starvation, or PKM2 inhibition to facilitate SSP expression (Fig. 3B(ii)) (53). However, MDM2
mediated SSP transcription still requires ATF4 transactivation. Nutrient deprivation such as
glucose, glutamine, or serine/glycine triggers c-MYC transcription in hepatocellular carcinoma
(HCC) cells (Fig. 3B(iii)) (54). c-MYC can promote SSP transcription via binding to their proximal
promoters to adapt the cells to the stress conditions, while the involvement of ATF4 in this scenario
is unclear. Together, these findings indicate the relevance of oncogenic drivers and stress
responses to coordinately activate SSP transcription and serine biosynthesis in various tumors.
Functional cross-talk between glycolysis and serine biosynthesis
As described above, oncogenic activation or nutrient-limitations can induce SSP gene
expression. However, serine biosynthesis not only depends on the expression of SSP genes but
also on the availability of substrate, mainly glycolytic derived 3-phosphoglycerate. Therefore,
alteration in glycolytic flux can substantially influence activity through the SSP.
In maximizing high glucose uptake, tumor cells promote the accumulation of glycolytic
intermediates for anabolic processes through reducing glycolytic flux through pyruvate (55).
Specifically, tumor glycolytic flux can be regulated by pyruvate kinases that catalyze the final and
irreversible step in glycolysis: ATP and pyruvate production from phosphoenolpyruvate (PEP) via
phosphate transfer to ADP. Mammals have four different kinds of pyruvate kinases. While PKL
and PKR are transcribed from the same gene, they are driven from different promoters and
expressed in liver and red blood cells, respectively. PKM1 and PKM2 are transcribed from the PKM
gene and arise via alternative splicing of exons 9 and 10, which leads to differential expression in
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tissues. While other pyruvate kinases form constitutively active tetrameric enzymes, PKM2 can be
found in either a highly active tetrameric or low active dimeric state. Tumor cells predominantly
express PKM2, as low active dimeric PKM2 allows for the accumulation of glycolytic intermediates.
In addition, tumor cells have developed a variety of mechanisms to disrupt tetramer formation and
preserve the low active PKM2 dimer, including allosteric regulation by metabolites, posttranslational modifications, and protein:protein interactions (56).
Mechanistically, PKM2 functions as a key node between glycolysis and serine
biosynthesis. As serine is an allosteric activator of PKM2, serine binding to PKM2 induces tetramer
formation and consequently increases pyruvate kinase activity to promote glycolytic flux to lactate
(57). Conversely, serine starvation reduces the pyruvate kinase activity in PKM2 expressing cells
to divert the glycolytic flux into serine biosynthesis through 3-phosphoglycerate availability. When
the intracellular serine level is restored, glycolytic flux is re-established by elevated activity of
PKM2. Therefore, PKM2 acts as a sensor for intracellular serine levels. To explore the relationship
between PKM isoforms and serine, Ye et al. generated ectopic PKM1 or PKM2 expressing cells in
endogenous PKM2 depleted H1299 cells (52). While the proliferation rate of PKM1 expressing cells
is comparable to PKM2 expressing cells in serine replete conditions, PKM2 expressing cells
displays better survival ability than PKM1 expressing cells under serine depleted conditions. This
supports the concept that PKM2 links the glycolytic pathway to serine metabolism. Further, receptor
tyrosine kinase activity contributes to serine biosynthesis via blocking tetramer formation by
phosphorylating PKM2 at Tyr105 (58). However, induction of tetramer formation of PKM2 by
CARM1 methylation impacts serine biosynthesis in MEF cells, further highlighting the link between
serine biosynthesis and PKM2 oligomeric status (59).
Given the reported pro-tumorigenic effects of diminished activity of dimeric PKM2, different
PKM2 activators have been developed as anti-cancer therapeutics. These small molecules induce
tetramer formation and block the phospho-tyrosine protein interaction induced dimer formation (60,
61). Interestingly, although these activators induced tetramer formation of PKM2 in tumor cells, no
significant cell proliferation difference was observed between activator-treated and untreated cells
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under standard cell culture conditions in vitro (62). However, PKM2 activators blocked cell
proliferation when serine is depleted from the media. Mechanistic studies demonstrated that PKM2
activators induce an acute increase in pyruvate kinase activity that led to a reduction in intracellular
glucose-derived biomolecules, including serine. This, in turn, induced expression of SSP genes
and serine transporters, SLC1A4 and SLC1A5, to restore the intracellular serine level (60, 61). As
serine biosynthetic activity is limited by lack of substrate production (low 3-PG levels due to high
PKM2 activity), tumor cells become dependent on exogenous serine to survive, thereby explaining
why the anti-tumorigenic actions of PKM2 activators require serine-limited conditions in vitro. In
short, the metabolic link between PKM2-regulated glycolysis and serine metabolism is mutual as
serine biosynthesis needs low active PKM2 while serine itself can act as an allosteric activator of
PKM2.
Phosphoserine aminotransferase 1
Since PHGDH is the rate-limiting enzyme in the SSP, there is considerable literature
describing its tumorigenic activities. Yet, the contribution of other SSP enzymes, including PSAT1,
is just now being investigated, which is the focus of this dissertation. As stated above, PSAT1 is
the second enzyme within the serine synthesis pathway that catalyzes the amino transfer from
glutamate to synthesize phosphoserine. Neu–Laxova syndrome (NLS) is a rare autosomal
recessive serine deficiency disorder with a broad range of manifestations. Several mutations in
PSAT1 have been discovered in NLS patients (63). Computational modeling of PSAT1 with patientderived mutations has found that while the A99V mutation is related to protein instability, S179L
affects the cofactor binding sites (64). Sirr et al. has conducted yeast complementation assays to
explore the functions of patient-derived PSAT1 mutations in SER1 (yeast ortholog of PSAT1)
knockout yeast and categorize the mutations based on survival effects (65). Consistent with
computational modeling, expression of S179L-PSAT1 mutant fails to rescue the growth of SER1
knockout yeast cells under serine-deprived media, demonstrating the importance of PSAT1
function in serine biosynthesis.
PSAT1 correlates with clinical outcomes
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Upregulation of PSAT1 expression has been discovered in a variety of tumor types in
comparison with normal tissue (1, 43, 66-72). Furthermore, higher PSAT1 correlates with
metastasis, advanced tumor stage, and poorer overall survival in ovarian cancer, triple-negative
breast cancer, ER-negative breast cancer, nasopharyngeal carcinoma, and esophageal squamous
cell carcinoma (ESCC) (43, 67, 69, 73). These clinical data strongly suggest a role for PSAT1 in
tumor progression. As colorectal cancer (CRC) patients with chemoresistance and breast cancer
patients with tamoxifen resistance display higher PSAT1 expression than patients with
chemosensitive lesions, elevated PSAT1 expression can serve as a prognostic marker for
chemotherapy (66, 74-76).
Regulation of PSAT1 expression in tumorigenesis
Coordinated regulation of SSP gene expression was detailed in earlier sections within this
introduction. Apart from these, other reported mechanisms directly regulate PSAT1 expression
(Fig. 4).
Elevated Psat1 expression has been observed in genetic models used in cancer research.
In mouse models for Kras mutant lung cancer, deletion of neurofibromin 1 (Nf1) leads to
upregulation of Psat1 expression (68). Further analysis has found that hyperactivation of focal
adhesion kinase 1 (Fak1) upon Nf1 deletion accounts for the upregulation of Psat1, which was
validated by Fak1 activator treatment of Nf1 wild-type cells. These findings were also recapitulated
with NF1 mutant and wild-type human patient-derived xenograft (PDX) cells. In the Kras mutant
pancreatic cancer model, deletion of liver kinase b1 (Lkb1) tumor suppressor gene was found to
increase Psat1 expression through AMPK/mTOR pathway activation (46).
Apart from these oncogene-driven cancer models, PSAT1 expression can also be
regulated epigenetically. Up-regulation of PSAT1 expression in CRC cells is mediated by G9A
histone H3K9 methyltransferase (77). Increased monomethylation of histone H3K9 in the PSAT1
promoter region activates PSAT1 transcription. G9A-mediated PSAT1 expression contributes to
several oncogenic processes, including cell migration, invasion, and cell proliferation.
investigation
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Figure 4. Regulation of PSAT1 expression in cancer. A) Genetic drivers that induce
PSAT1 expression. B) Epigenetic regulation of PSAT1. C) miRNA-mediated regulation of
PSAT1.
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conducted with ER-positive breast cancer patients found that the PSAT1 promoter is
hypermethylated and correlates with low PSAT1 expression, thereby implying the involvement of
epigenetic mechanisms on PSAT1 expression in ER-positive breast cancer (75). Survival analysis
demonstrated that both PSAT1 promoter hypermethylation and low mRNA expression are
associated with better outcomes after tamoxifen treatment.
MicroRNAs can participate in tumorigenesis via regulating mRNA translation and can be
oncogenic or tumor suppressive depending on their target proteins and expression ratio between
tumor and normal tissue. Down-regulated miRNAs in tumor tissue are expected to function as
tumor suppressers and miRNA-mediated PSAT1 expression has been reported in some cancers.
Mir-340 and miR-365 are two low expressed miRNAs in ESCC that may regulate PSAT1 and their
expression negatively correlate with PSAT1 in tumor tissue (77, 78). Ectopic expression of these
miRNAs in ESCC cells decreases cell proliferation, invasion, and colony formation in vitro and
tumor growth in vivo, as well as PSAT1 expression. Restoration of PSAT1 expression in miRNA
overexpressed cells mitigates their tumor suppressive functions. miR-195-5p has been identified
as a tumor suppressor miRNA in ovarian cancer due to loss of expression in tumor tissue and
restoration of chemosensitivity to cisplatin upon overexpression (79). PSAT1 has been found as a
direct target of miR-195-5p. While PSAT1 silencing recapitulates the miR-195-5p overexpression
mediated phenotype, increased PSAT1 reverts it, suggesting that loss of miR-195-9p contributes
to elevated expression of PSAT1 in ovarian cancer. PSAT1 in CRC cells is not only subjected to
epigenetic regulation by G9A histone H3K9 methyltransferase but also loss of miR-424 (80, 81). A
negative correlation between miR-424 expression and PSAT1 expression has been shown in CRC
tissue. While miR424 expression leads to growth inhibition and apoptosis induction, overexpression
of PSAT1 impacts the miR424-mediated anti-tumorigenic phenotype.
PSAT1 metabolic function in tumorigenesis
Several studies have reported an oncogenic function of PSAT1, but few provide direct
evidence for its metabolic function through a rescued phenotype by metabolite supplementation.
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According to gene expression analysis from the TCGA database, high levels of PSAT1
correlates with the proliferation rates of many types of tumors (82). As Lkb1 loss in the Kras mutant
pancreatic cancer mouse model induces Psat1 expression, Psat1 depletion affects the cell
proliferation and anchorage-independent growth in these cells but not in Lkb1 wild-type cells (46).
Rescue studies with down-stream metabolite supplementation reveal that Psat1 is crucial in
supplying SAM for cell proliferation but not to maintain nucleoside pools or redox homeostasis.
Suppression of PSAT1 in ovarian cancer cells induces apoptosis and cell cycle arrest and
impairs clonogenic growth (73). Consistent with these findings, silencing leads to reduction in cyclin
D1 and CDK4 expression and increased in BAX and cleaved caspase3 levels. Further analysis of
PSAT1 mediated-metabolic pathways has shown decreased reduced glutathione (GSH)/ oxidized
glutathione (GSSG) ratio and increased ROS levels under PSAT1 silencing, which is restored via
GSH supplementation.
As mentioned above, loss of Nf1 tumor suppressor in Kras mutant lung cancer mouse
model increases the Psat1 expression (68). While inhibition of Psat1 activity with transaminase
inhibitor severely affects cell proliferation, preincubation of the cells with α-KG abolishes the effect
of inhibitor treatment, suggesting an anaplerotic requirement of Psat1 expression in these cells.
The oncogenic role of PSAT1 via mediating glycogen synthase kinase 3 beta (GSK3β)
pathway
Despite the presence of several reports showing the oncogenic function of PSAT1, the
involvement of PSAT1 in downstream signaling pathways requires further investigation. According
to previous studies, PSAT1 is linked to a GSK3β-dependent pathway. Increased phosphorylation
of GSK3β at Ser9 upon elevation of PSAT1 has been found in many tumor cell types even though
the downstream effector may be context-dependent. In general, phosphorylation of GSK3β at Ser9
inhibits its serine/threonine kinase activity and phosphorylation-dependent proteasomal
degradation of target proteins (83, 84). Figure 5 summarizes the PSAT1-GSK3β pathway in
tumorigenesis.
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Figure 5. The oncogenic function of PSAT1 mediated by GSKβ pathway.
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Yang et al. found that cyclin D1 expression at the protein level decreases in PSAT1
silenced NSCLC cells and increases upon overexpression, which is independent of transcriptional
regulation (1). Further analysis shows that high PSAT1 leads to increased phosphorylation of
GSK3β at Ser9 and inhibits GSK3β-dependent cyclin D1 phosphorylation at T286. Decreased
phosphorylation protects cyclin D1 from proteasomal degradation, resulting in the accumulation of
cyclin D1, which increases cell cycle progression via enhancing E2F activity.
The role of PSAT1 in ER-negative breast cancer cells has been investigated via both
silencing and ectopic expression (43). PSAT1 mediates cell proliferation, cell cycle progression,
and colony formation in vitro and tumor growth in vivo. A mechanistic study revealed that high
PSAT1 expression correlates with the inhibitory phosphorylation level of GSK3β (Ser9). Inhibition
of GSK3β activity leads to accumulation and nuclear localization of -catenin in breast cancer cells
and subsequently increases expression of cyclin D1. Therefore, PSAT1 is involved in ER-negative
breast cancer proliferation and cell cycle progression, in part, via regulation of the GSK3β/βcatenin/cyclin D1 pathway.
Dai et al. also demonstrated the connection between PSAT1 and GSK3β/β-catenin
pathway in ovarian cancer (79). Restoration of low expressed miR-195-5p in ovarian cancer
reduces phosphorylated GSK3β levels and β-catenin. As PSAT1 has been found as a direct target
of miR-195-5p, overexpression of PSAT1 in miR-195-5P expressing cells reconstitutes
phosphorylated GSK3β and β-catenin expression. Reduced sensitivity to cisplatin treatment upon
PSAT1 overexpression or β-catenin agonist treatment indicates that this PSAT1/GSK3β/β-catenin
pathway is involved in chemoresistance in ovarian cancer.
Liu et al. examined the role of PSAT1 function in ESCC cells via loss and gain of function
studies (69). Modulation of PSAT1 expression in ESCC alters cell proliferation and invasion in vitro
and tumor growth in vivo. PSAT1 expression correlates with inhibitory phosphorylation of GSK3β
and downstream SNAIL-mediated expression of E-cadherin and vimentin. Consistent with this
finding, observation from PSAT1 targeting miRNAs, miRNA-340 and miR-365, suggest that PSAT1
has an oncogenic function in ESCC cells via regulating the GSK3β/SNAIL pathway (69, 77, 78).
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PSAT1 contribution to lung tumorigenesis
Integrative transcriptomic and proteomic analyses of samples derived from both primary
and PDX lung tumors have been performed in attempts to discover genes with prognostic value
(85). Increased PSAT1 has been observed in both primary and PDX NSCLC tumors, and it is
upregulated in NSCLC tumor-initiating cells and induces cellular transformation of 3T3 cells (86).
Together, these suggest PSAT1’s involvement in lung tumorigenesis.
Within the serine-one carbon metabolic pathway, Yang et al. found that PSAT1 is the most
upregulated enzyme in NSCLC tumors (1). Immunohistochemistry (IHC) staining of lung cancer
tissue validates the upregulation of PSAT1 in NSCLC and its association with poorer patient
outcomes. E2F has been identified as a potential downstream regulator of PSAT1, which is evident
from reporter assays with decreased E2F transactivation upon PSAT1 silencing in lung cancer
cells. Consistent with this, suppression of PSAT1 impairs cell proliferation and cell cycle
progression and correlates with hypo-phosphorylated retinoblastoma (RB) protein.

Further

examination shows that PSAT1 leads to the accumulation of cyclin D1 in NSCLC cells through
inhibiting GSK3β-induced phosphorylation and degradation. Therefore, they conclude that PSAT1
can mediate cell cycle progression, cell proliferation, and colony formation in vitro and tumor growth
in vivo through regulating the GSK3β /cyclin D1/RB/E2F pathway in NSCLC cells.
Chan et al. investigated the role of PSAT1 in lung adenocarcinoma metastasis (2).
Evaluation of publicly available datasets demonstrated that high expression of PSAT1 expression
is associated with poorer overall and disease-free survival of patients with lung adenocarcinoma.
Highly metastatic CL1-5 cells have increased PSAT1, while depletion of PSAT1 impacts this
invasion capacity both in vitro and in vivo (2, 87). The involvement of PSAT1’s metabolic activity
in cell invasion has been tested via altering glucose, glutamine, and serine. After observing
unaffected cell invasion upon metabolic manipulations, they concluded that PSAT1 mediated cell
invasion is independent of its metabolic function. PSAT1-mediated genome-wide gene expression
profiling suggested that PSAT1 participates in lung cancer metastasis by suppressing
STAT1/IRF1/IFIH1 pathway.
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EGFR mutant lung cancer
In this work, we investigated a role for PSAT1 under EGFR activation. Activating mutations
within EGFR are found in a substantial percentage of NSCLC and were used as the model system
for these studies. For this, the following section briefly introduces the function of EGFR mutations
in lung tumorigenesis.
EGFR mutations in NSCLC
Lung cancer is the leading cause of cancer-related deaths in the US with an overall fiveyear survival rate of 19% (88). NSCLC accounts for 84% of lung cancer cases with another 13% of
cases classified as small cell carcinoma. Surgery is the primary treatment option for NSCLC
patients diagnosed at early stage, but more than 55% of new cases are diagnosed at advanced
stages with distant metastasis (89).
Smoking is a major risk factor for developing lung cancer and is responsible for 80% of
lung cancer deaths in the US (88). However, approximately 20% of lung cancer cases are observed
in never-smokers. Adenocarcinoma is the most common histologic sub-type of NSCLC and 60%
of the cases are related to oncogenic-driver mutations. Among these, activation mutations within
the EGFR tyrosine kinase region constitute 17% of genetic alterations in adenocarcinoma and are
significantly found in never smokers (90).
EGFR belongs to the ErbB family of tyrosine kinase receptors, which is genetically
localized to chromosome 7p12 (91). It is comprised of an N-terminal extracellular ligand-binding
domain, single-span transmembrane domain, intracellular tyrosine kinase domain, and regulatory
C-terminal region (92). Epidermal growth factor (EGF), transforming growth factor α (TGFα), and
amphiregulin (AREG) are all ligands that bind to and induce receptor dimerization, resulting in
tyrosine kinase activation. Subsequently, several tyrosine residues at the C-terminal region are
transphosphorylated and function as docking sites for proteins involved in the activation of
downstream pathways such as PI3K/AKT/mTOR, RAS/MAPK, and the JAK/STAT (92-95).
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Activation of EGFR signaling promotes several tumorigenic processes, including cell proliferation,
survival, migration, angiogenesis, and metastasis (91, 92).
The observation of dysregulated EGFR signaling in multiple tumor types led to the
development of targeted therapies (92, 96, 97). Inhibition of ligand binding by monoclonal EGFR
antibody or blocking tyrosine kinase activity by small-molecule antagonists are two distinct
approaches to suppress EGFR signaling. Although monoclonal antibody treatment improves
patient outcomes within colorectal and laryngeal cancers, the effect on lung cancer is controversial
(98). Gefitinib and erlotinib are first-generation EGFR tyrosine kinase inhibitors (TKI). Gefitinib
was initially developed as a tyrosine kinase inhibitor in 2003. It was initially administered to
unselected lung cancer patients, with only 10% of them demonstrating any response to therapy
(92). Stratification of the gefitinib-treated patients found that a subgroup of NSCLC patients with
adenocarcinoma histology and never-smoking status from East Asian females are associated with
the higher response rate to treatment. Further investigation within this group led to the discovery of
mutations in the EGFR tyrosine kinase region that predicts gefitinib response (91, 92, 94). The
discovery of mutated EGFR and the presence of small-molecule inhibitors have provided the
opportunity to explore EGFR signaling, particularly as it relates to the metabolic enzyme functions
highlighted in this dissertation.

Metabolic alterations are driven by mutant EGFR

Makinoshima et al. examined glycolytic metabolism in EGFR mutant lung cancer via
EGFR-TKI treatment (99).

Inhibition of EGFR signaling decreases glycolytic activity as

demonstrated by lower lactate production, glucose consumption, and glucose-derived extracellular
acidification rate (ECAR). Consistent with these results, hexokinase II (HK II) and glucose
transporter 3 (GLUT3) expression are down-regulated in response to treatment. Metabolite
analysis has found that the pentose phosphate pathway (PPP) and redox metabolism are also
affected. Furthermore, EGFR signaling may contribute to pyrimidine biosynthesis via
phosphorylating

and

activating

CAD

(carbamoyl-phosphate

synthetase

2,

aspartate

transcarbamylase and dihydroorotase). In another study, De Rosa et al. also found that TKIs

21

reduce lactate production, HK II expression, and phosphorylation of PKM2 at Y105 (100). Yet, they
also observed increased oxygen consumption, expression of mitochondrial complexes, and ATP
production that indicated increased oxidative phosphorylation, suggesting that activating mutations
in EGFR impacts not only glycolysis but also oxidative phosphorylation. EGFR-mediated glycolysis
was further confirmed via EGFR knockdown, which decreased many of the genes involved in
glycolysis (101). Glycolysis is crucial to sustain TCA cycle intermediates in EGFR mutant cells and
both glucose starvation and inhibition of mitochondrial activity induce apoptosis. Mechanistic
studies found that inhibition of mitochondrial ATP production induces autophagy-mediated
degradation of EGFR protein. Taken together, glycolytic activity is not only driven by EGFR
oncogenic activity but is also required for EGFR stability in EGFR mutant lung cancer.

The role of receptor tyrosine kinases (RTKs) in lung cancer metabolic reprogramming has
been investigated via gain of function studies (50). Metabolic tracing experiments with

13C-labeled

glucose, glutamine, and palmitate were done in BAF3 isogenic cells stably transfected with mutant
forms of RTKs including EGFR, FGFR, RET, and MET. Among these, mutant EGFR yielded higher
glucose-derived serine biosynthesis and inhibition of serine biosynthesis impairs cell proliferation.
These findings were further corroborated with EGFR mutant cell lines using PHGDH inhibitor
treatment, indicating that activation mutation in EGFR promotes serine biosynthesis. Further
upregulation of PHGDH has been shown in erlotinib resistance cells and inhibition of activity via
either inhibitor or silencing induces the sensitivity (47). Another study supports this via ectopic
expression of PSAT1 in EGFR mutant HCC827 NSCLC cells, which induces resistance to EGFRTKI treatment (70). Thus, these reports imply that while EGFR mutation activates serine
biosynthesis, it is further enhanced under TKI resistance.

The relationship between glutamine metabolism and EGFR mutation has been
demonstrated using glutaminase (GLS) inhibition (102). In a xenograft tumor model, suppression
of GLS activity does not affect tumor growth but enhances the anti-tumor activity of erlotinib.
Molecular analysis has found that glycolysis and glutaminolysis are inhibited by combination
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therapy, which negatively impacts the cellular energetic status and subsequently results in AMPKmediated cell death.

Monounsaturated fatty acid (MUFA) synthesis is associated with the activation of lipid
metabolism in tumorigenesis. Investigation of molecular mechanism in lung cancer has found that
stearoyl-CoA desaturase 1 (SCD1), which plays a role in MUFA synthesis, interacts with EGFR in
EGFR mutant cells (103). This interaction contributes to SCD1 protein stability via EGFR-mediated
phosphorylation at Y55 and promotes lipid synthesis for tumor growth.

In short, mutant oncogenic activation of EGFR signaling modulates a variety of enzymes
within metabolic pathways. These changes may not only involve manipulation of their canonical
activities but also putative alternative functions, all of which may allow for the development of
EGFR-TKI resistance.
Metabolic enzymes with non-canonical functions in tumorigenesis
The observation of metabolic reprogramming in tumor cells prompted researchers to
examine specific enzyme function under varying conditions, including oncogenic activation, nutrient
limitation, and hypoxia. This has provided significant insight into their involvement in tumorigenesis
(104). In some cases, supplementation of downstream metabolites failed to rescue a loss of
function phenotype, whereas restoration of a catalytically inactive enzyme rescued the cellular
phenotype under specific conditions. This implied that certain metabolic enzymes possess a novel
tumorigenic function beyond their role in metabolic pathways (105-107). To date, non-canonical
functions have been discovered for multiple metabolic enzymes, particularly those involved in the
glycolytic and TCA cycle pathways (104).
In many cases, non-canonical functions of enzymes are induced by post-translational
modification, relocalization into a different cellular compartment, and /or interaction with nonmetabolic proteins. In other cases, elevated expression of the enzyme is sufficient to display noncanonical functions (108).
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Non-canonical functions can be categorized into two groups based on the requirement of
catalytic activity. In the catalytic-dependent pathway, metabolic enzymes follow one of two routes
to exert their non-canonical functions. Either they expand their substrate specificity from small
metabolites to protein targets, resulting in protein modifications, or translocating to a different
cellular compartment where their metabolic products are utilized as co-factors or substrates for
posttranslational modifications (104, 108). In the catalytic-independent pathway, they can modify
associating protein function via their physical interaction (104).
Catalytic-dependent non-canonical functions
i) Proteins, not metabolites, serve as substrates for metabolic enzymes
Various metabolic enzymes with kinase activity can exhibit protein kinase function using
proteins as a substrate instead of their defined metabolites (108, 109). PKM2 has been the moststudied metabolic enzyme with protein kinase activity that influences several tumorigenic
processes. One distinction is that it transfers the phosphate from PEP to protein targets instead of
ATP. Mitogenic and growth factor stimulation, particularly EGF, leads to nuclear localization of
PKM2 by post-translational modifications (110). Nuclear PKM2 can phosphorylate STAT3 at
Tyr705 and Histone H3 at Thr11 that subsequently induces the expression of genes involved in cell
proliferation, migration, and the Warburg effect (111, 112). Restoration of a catalytically inactive
mutant of PKM2 in endogenous PKM2 depleted cells fails to restore the phosphorylation level of
Histone H3 and the phenotype even though it can translocate into the nucleus (111, 113). Similarly,
nuclear localization mutant forms of PKM2 decrease protein phosphorylation even though they
have intact catalytic activity (110, 114). In the mitotic process, PKM2 participates in different steps,
including phosphorylating Bub3 in chromosome segregation and phosphorylating MLC2 in
cytokinesis (115, 116). In addition, the protein kinase activity of PKM2 contributes to cell survival
in response to oxidative-stress induced apoptosis (117).

PKM2 can translocate into the

mitochondria upon oxidative stress and phosphorylate BCL2. Phosphorylated BCL2 is resistant to
proteasomal degradation and promotes cell survival. These are just a few examples of the non-
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canonical oncogenic functions of PKM2, whose roles can also be extended to tumor cell secretion,
migration, and DNA damage response (108).
Phosphoglycerate kinase 1 (PGK1) is another ATP generating enzyme within the glycolytic
pathway that utilizes the intermediate 1,3-diphosphoglycerate (108). Like PKM2, PGK1 also
displays protein kinase activity, but unlike PKM2, it uses ATP as a phosphate source. Hypoxic
activation of ERK signaling, EGFR stimulation, expression of mutant KRAS and BRAF induce
PGK1 phosphorylation at S203 and mitochondrial localization (118). Mitochondrial PGK1 activates
pyruvate dehydrogenase kinase isozyme 1 (PDHK1) through phosphorylation at T388.
Phosphorylated PDHK1 subsequently inhibits the activity of pyruvate dehydrogenase complex
(PDC), resulting in decreased pyruvate oxidation in mitochondria and increased pyruvate
conversion to lactate in the cytosol. This suggests that PGK1 not only contributes to glycolytic flux
through its canonical activity but also by inhibiting the usage of pyruvate by the mitochondria.
Separately, glutamine starvation and hypoxia lead to mTOR-dependent phosphorylation of ARD1,
which results in binding to PGK1 and acetylation at K388 in glioblastoma (GBM) cells (119).
Acetylated PGK1 initiates autophagosome formation via phosphorylating Beclin1 at S30. The
correlation between acetylated PGK1 and Beclin1 phosphorylation has been supported by GBM
human tumor data and is associated with poor patient outcomes.
ii) Metabolites serve as substrates or cofactors for other enzymes
In some cases, nuclear-localized metabolic enzymes supply metabolic products that allow
for global changes in histone modifications (108, 120). For example, acetyl-CoA for histone
acetylation can be generated by nuclear ATP-citrate lyase (ACLY) using citrate or nuclear PDC
using pyruvate (121, 122). While oncogenic signaling promotes nuclear localization of ACLY by
AKT-dependent phosphorylation, serum and EGF stimulation can trigger the nuclear localization of
PDC.
Tumor cells can also utilize metabolic enzymes to regulate gene expression within a
specific locus by their translocation into the nucleus and complex formation with specific chromatinmodifying enzymes (108, 123). As further detailed below, metabolic enzymes within protein
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complexes provide substrates for the chromatin-modifying enzymes and contribute to the
regulation of gene expression.
Sivanand et al. demonstrated that induction of DNA damage by ionizing radiation (IR) leads
to phosphorylation of ACLY at S455 (124). This is required for histone acetylation near doublestrand breaks (DSB) and recruitment of BRCA1 for homologous recombination (HR) repair.
Furthermore, reconstitution of neither inactive mutant ACLY nor nuclear export signal (NES) tagged
ACLY in ACLY depleted cells are able to promote HR-dependent DBS repair, implicating the
importance of nuclear-localized active ACLY function. Fumarate hydratase (FH) is an enzyme
within the TCA cycle that catalyzes the reversible conversion of fumarate to malate (108). However,
a recent study reported a novel nuclear function for FH in IR-induced DSB repair (125). After
nuclear localization of FH in response to IR treatment, DNA-PK phosphorylates FH at T236 that
promotes its interaction with histone H2A.Z at the DSB site. Fumarate production by DSB localized
FH inhibits the histone demethylase activity of KDM2B. This results in enhanced dimethylated
H3K36 at DSB sites, which is required for non-homologous end-joining (NHEJ) DNA repair complex
recruitment. While the addition of high levels of fumarate restores NHEJ-mediated DNA repair in
FH depleted cells, the expression of an inactive mutant does not. Thus, these studies implicate the
importance of a locally produced metabolite in DNA damage repair.
Under glucose limitation, tumor cells can activate autophagy to survive. As nuclear acetylCoA levels are impacted due to limited substrates for ACLY and PDC activity, activation of
autophagy-related gene expression still requires histone acetylation. Li et al. found that glucose
deprivation triggers AMPK-mediated phosphorylation of acetyl-CoA synthetase 2 (ACSS2) at S659,
which leads to nuclear localization (126). Nuclear ACSS2 interacts with transcription factor EB
(TFEB) and forms a transcription complex to initiate lysosomal and autophagy gene expression via
binding to their promoter regions. ACSS2 within this complex locally produces acetyl-CoA for
histone acetylation.
Alpha-ketoglutarate dehydrogenase (α-KGDH) is another well-known TCA cycle enzyme
that produces succinyl-CoA from α-KG and acetyl-CoA and has also been observed in the nucleus
(127). Nuclear α-KGDH interacts with lysine acetyltransferase 2A (KAT2A) and leads to
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succinylation of histone H3K79 near the promoter region. Inhibition of nuclear localization of αKGDH or disruption of the succinyl-CoA binding site of KAT2A (Y645A) suppresses gene
expression, cell proliferation, and tumor growth, thereby showing the importance of nuclear αKGDH produced succinyl-CoA in tumorigenesis.
Proteomic analysis of MafK associating partners found nuclear localization of methionine
adenosyl transferase IIα (MatIIα), suggesting a mechanism for local SAM production (128). Mat IIA
within the MafK-associated complex leads to gene repression of the heme oxygenase-1 gene (Ho1). Further, MatIIα forms a complex with chromatin-modifying proteins such as Swi/Snf and NuRD
and provides SAM for histone methylation.
In short, the relocalization of metabolic enzymes into a different cellular compartment can
be exploited by tumor cells for the epigenetic regulation of gene expression and DNA-damage
repair, resulting in cell survival and tumor growth.
Catalytic-independent non-canonical functions
Metabolic enzymes can also exert non-canonical functions via interacting with nonmetabolic proteins, relocalization into a different cellular compartment, or both in a catalytic
independent manner (104). In this scenario, reconstituted expression of catalytically inactive
mutant forms restores the phenotype in endogenous protein depleted conditions, while inhibition of
metabolic activity by inhibitor treatment does not significantly affect the phenotype.
Dimeric PKM2 can bind to the phosphorylated-tyrosine residue of proteins (129).
Changing the amino acid residue from K433 to 433E by site-directed mutagenesis leads to loss of
this ability. In EGFR mutant lung cancer cells, the interaction between PKM2 and mutant EGFR
sustains EGFR signaling by inhibition of proteasomal degradation of EGFR (130). While
catalytically inactive PKM2 still contributes to EGFR stability, the half-life of mutant EGFR is
reduced upon either PKM2 activator treatment or mutant PKM2 (K433E) expression. In GBM cells,
nuclear PKM2 binding to HuR blocks HuR-dependent p27 translation via retaining HuR in the
nucleus (131). Depletion of PKM2 leads to cell cycle arrest due to HuR-mediated p27 translation
while reconstituted wild-type and catalytically inactive mutant PKM2, but not the K433E mutant,
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can restore cell cycle progression. Phosphoglycerate mutase 1 (PGAM1) is another glycolytic
enzyme with an identified non-canonical function, which is independent of its catalytic activity (107).
While investigating a novel function for PGAM1, alpha-smooth muscle actin (ACTA2) was identified
as a PGAM1 interacting protein. PGAM1 plays a key role in F-actin formation and cell migration via
interacting with ACTA2 and inhibition of metabolic activity by either mutation or inhibitor treatment
does not affect this interaction and cell motility.
Contrary to oncogenic roles for non-canonical functions of metabolic enzymes, nuclear
malate dehydrogenase 1 (MDH1) and nuclear fructose-1,6-bisphosphatase 1 (FBP1) exhibit tumor
suppressor functions (106, 132). Glucose starvation induces nuclear localization of MDH1. Nuclear
MDH1 interacts with p53 that results in decreased proteasomal degradation and induction of gene
expression via acting as a co-activator for p53 (106). Transactivation of p53 target genes, including
BAX, triggers apoptosis. Glucose deprivation-induced apoptosis has not been observed in MDH1silenced, p53 proficient cells or MDH1 overexpressed p53-deficient cells. However, reconstituted
catalytically inactive MDH1 expression in p53 proficient cells exhibits increased apoptosis,
confirming that nuclear MDH1-p53 interaction mediates apoptosis in glucose-limited conditions in
a metabolic independent manner. Loss of FBP1 has been found to play a role in clear cell renal
carcinoma (ccRCC) tumorigenesis and is associated with poor prognosis (132). Nuclear FBP1
inhibits hypoxia-inducible factor (HIF) target gene expression via interacting with the inhibitory
domain of HIF1α and HIF2α in VHL tumor suppressor deficient cells. While expression of
catalytically inactive mutant FBP1 still abolishes HIF-dependent gene expression and cell
proliferation under normoxia, expression of NES-tagged FBP1 cannot recapitulate the phenotype
of wild-type FBP1 activity, indicating that the nuclear, catalytic-independent function blocks HIF
transactivation.
Non-canonical function of genes involved in the serine synthesis pathway
As mentioned above, many reports have defined the non-canonical functions of glycolytic
and TCA cycle enzymes in tumorigenesis. Although we speculate that SSP enzymes may also
possess non-canonical functions, few reports have identified novel functions for the SSP proteins.
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PHGDH has been found as a potential prognostic marker for GBM (133). Silencing of PHGDH
inhibits cell proliferation, migration, and invasion. Further study has shown that PHGDH contributes
to these oncogenic processes via increasing protein stability of FOXM1 by physical interaction that
promotes the expression of genes involved in cell migration and invasion. Another study found that
PHGDH interacts with the translation initiation factors, eIF4A1 and eIF4E, in pancreatic
adenocarcinoma and involves the translation initiation process via increasing complex stability,
especially under nutrient-stress conditions (134). Pharmacological inhibition of PHGDH activity
does not alter the interaction with this initiation complex and translation of mRNAs, including Ecadherin and ZO-1, but the suppression of PHGDH expression abolishes complex formation and
affects translation initiation of the relevant mRNAs. Separate from these non-canonical functions,
PHGDH can produce the oncometabolite D-2-hydroxyglutarate (D-2-HG) from α-KG (135). D-2-HG
acts to competitively inhibit α-KG-dependent dioxygenases, which results in reduced histone and
DNA demethylation. Therefore, it will be intriguing to investigate whether PHGDH-produced 2-HG
can alter the epigenetic landscape of tumor cells.
PSPH is the final enzyme within the serine biosynthetic pathway and produces serine via
removing phosphate from phosphoserine. A recent study has reported that PSPH also
dephosphorylates serine phosphorylated peptides, implicating a potential protein phosphatase
activity in vitro (105). Insulin Receptor Substrate 1 (IRS1) has been found as a protein substrate
for PSPH phosphatase activity due to its interaction with PSPH and the reduction of S794
phosphorylation level upon PSPH overexpression in NSCLC cells. Removal of inhibitory phosphate
from IRS-1 (S794) initiates the activation of the AKT1-mTORC pathway and cell migration and
invasion. Yet, the restoration of inactive mutant PSPH expression in PSPH silenced cells fails to
dephosphorylate IRS-1 at S794 and rescue the cell migration defect, supporting a non-canonical
function of PSPH.
On the other hand, the oncogenic function of PSAT1 has been implicated in many types of
cancer via loss and gain of functions, but a mechanistic study demonstrating a non-canonical
function of PSAT1 has yet been reported. For example, elevated expression of PSAT1 has been
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implicated in GSK3β mediated pathway in several cancer types but whether PSAT1’s canonical or
non-canonical function is crucial in the regulation of this pathway is yet to be determined (1, 43, 69,
79). The involvement of PSAT1 in epigenetic gene regulation has been shown in mouse embryonic
stem cell maintenance via supplying α-KG for dioxygenases leading to histone and DNA
demethylation, but then again, it is unknown whether PSAT1 displays such function for tumor cells
or if the compartmental specific expression is required (136).
As described above, non-canonical functions of metabolic enzymes have been observed
under specific conditions and each enzyme is regulated separately in order to exert its novel
function. This is highlighted by EGFR-mediated nuclear functions of PKM2 and PDC and indicates
that EGFR signaling does not only promote metabolic reprogramming but also induces noncanonical activities of target proteins (113, 122). Unraveling the non-canonical functions of
enzymes is experimentally challenging, but it is necessary to develop new cancer therapies.
We postulate that PSAT1 exhibits a non-canonical function in EGFR-mediated lung tumor
progression. This hypothesis was tested in multiple aims that utilized biochemical approaches to
identify new PSAT1 associating proteins (Aim1) and the impact of PSAT1 loss on an interacting
protein’s function and localization (Aim1). Aim 2 intended to define a cellular phenotype due to
PSAT1 silencing in NSCLC and undertake rescue studies to evaluate a role for a novel interacting
protein. Lastly, gene expression profiling was performed to characterize downstream genomic
changes and prognostic relevance of a PSAT1 associated gene signature in EGFR-mutant NSCLC
(Aim 3).
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CHAPTER 2
NUCLEAR PYRUVATE KINASE M2 (PKM2) CONTRIBUTES TO PHOSPHOSERINE
AMINOTRANSFERASE 1 (PSAT1)-MEDIATED CELL MIGRATION IN EGFR-ACTIVATED LUNG
CANCER CELLS

Introduction
The impact of metabolic reprogramming has been well accepted in cancer pathogenesis
(6, 137). Mainly, the contribution of the Warburg effect and glutamine addiction has been
extensively investigated in the growth and survival of multiple tumor types (138-140). More recently,
several reports have described additional functions for glycolytic enzymes in tumor progression
beyond their metabolic activities (141). For example, PKM2 can be translocated into the nucleus in
response to a variety of oncogenic signals and regulate gene expression, particularly through direct
interaction with transcription factors or by transcription factor phosphorylation by inherent PKM2
protein kinase activity (110, 111, 113, 114, 142). Through an interaction with ACTA2,
phosphoglycerate mutase 1 (PGAM1) mediates actin filament assembly and increases cell
migration and invasion in breast cancer (107). Although pro-tumorigenic functions of glycolytic
enzymes are well-established, the requirement for serine synthesis enzymes has only recently
been described (1, 15, 45, 105, 133).
De novo cellular production of serine may contribute to tumor growth by providing
precursors for macromolecular production and one-carbon metabolism (15). Accordingly, multiple
cancers exhibit increased expression of SSP enzymes (44, 71, 105, 133). For example, elevated
PSAT1, which catalyzes the second step in converting 3-phosphohydroxypyruvate to
phosphoserine, is associated with poorer clinical outcomes (1, 43, 67, 69, 70, 72, 74, 143, 144).
Depending on tumor type, several reports have implicated PSAT1 in the proliferation, migration,
invasion, and chemo-resistance of malignant cells (1, 43, 46, 69, 71, 74, 79, 143). Yet, the
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complete mechanism by which the serine biosynthetic pathway facilitates metabolic or cellula
changes necessary for tumor growth is still not fully understood (15). As observed with certain
glycolytic proteins, studies have also described non-canonical activities of SSP enzymes.
Phosphoglycerate dehydrogenase (PHGDH) contributes to glioma progression through direct
interaction and stabilization of FOXM1(133). Separately, phosphoserine phosphatase (PSPH) can
promote tumorigenesis through direct IRS1 dephosphorylation (105). While multiple studies
indicate a pro-tumorigenic role for PSAT1, alternative functions for this SSP enzyme have yet to
be fully described.
We now report a novel direct interaction between PSAT1 and PKM2. While the loss of
PSAT1 does not alter cellular PKM2 expression or activity, it disrupts PKM2 nuclear translocation
in response to EGFR-activation in lung cancer cells. In addition, PSAT1 silencing decreases
migration in these cell types, while PSAT1 restoration or overexpression promotes cell motility and
PKM2 nuclear localization. PSAT1 also undergoes nuclear translocation upon EGFR-activation,
but it is still unclear whether disruption of the PSAT1:PKM2 association alters nuclear
compartmentalization. Yet, re-expression of a nuclear localization signal (NLS) tagged PKM2
acetyl-mimetic (K433Q) mutant partially restores cell migration in PSAT1 suppressed cells. Taken
together, our findings suggest that PSAT1-promoted nuclear PKM2 translocation contributes, in
part, to cell migration under EGFR-activation in lung cancer.
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Materials and Methods
Reagents and antibodies
Erlotinib was purchased from (Selleckchem, OSI-744). Human recombinant proteins PKM2
(SAE0021), PKM1 (SRP0415), and EGF (E9644), anti-β-actin (A2228) antibody, PSAT1 shRNA
(TRCN0000291729), and control shRNA (SHC202) were purchased from Sigma-Aldrich.
Antibodies against PKM2 (4053), PKM1 (7067), OCT1(8157), 𝑎-Tubulin (3873), DYKDDDDK-Tag
(2368), and rabbit IgG (2729) were obtained from Cell Signaling Technology. Anti-PSAT1 (105011-AP) antibody was purchased from Proteintech Group Inc. The PSAT1 Double Nickase CRISPR
Plasmid system (sc-403001-NIC) was purchased from Santa Cruz Biotechnology.
GST-Pulldown and Mass Spectrometry
PSAT1 cDNA was subcloned into the pGEX4T-1 plasmid (Amersham) to generate pGEXGST-PSAT1 and tagged PSAT1 was induced in BL21 cells with IPTG. GST-PSAT1 was incubated
with one milligram of pre-cleared A549 lysate and columns were washed 3X and eluted with
reduced glutathione. Dialyzed elutes were separated by SDS-PAGE and protein bands were
detected by silver stain. Bands enriched in the GST-PSAT1 samples were excised and sent for
protein identification by mass spectrometry.
LC/MS data collection and analysis
Tryptic peptides were prepared from excised gel bands and analyzed using a liquid
chromatograph tandem mass spectrometry (LC-MS/MS) approach as previously described (145).
Briefly, peptides were separated on a 10cm C-18 (Jupiter 5-μm RP300A (Phenomenex) packed
needle tip using a 5% to 40% acetonitrile gradient at a flow rate of 200nl/min prior to
nanoelectrospray into an LTQ linear ion trap mass spectrometer (Thermo Fisher Scientific). Data
were acquired in a data-dependent fashion with a full MS scan (300-2000 m/z) followed by six
MS/MS scans (35% collision energy) and a 1-min dynamic exclusion window. MS/MS data were
searched by ProteomeDiscoverer (version 1.4) as previously described against a human refseq
protein database (version HumanRef140722.fasta with 88,942 entries) using SEQUEST (version
1.4.0.288) and Mascot algorithms (version 2.4) assuming 1.0Da fragment mass tolerance and
1.2Da parent mass tolerance, fixed modification of cysteine (+57 for carbamidomethylation),
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variable oxidation of methionine (+16 to methionine) and maximal two missed trypsin
cleavages(146). High-probability peptide and protein identifications were assigned using the
Peptide-/Protein-Prophet algorithms (http://tools.proteomecenter.org/software.php) and result
quantitatively using Scaffold v4.3.4 (ProteomeSoftware) using a spectral counting method.
Cell culture
A549 NSCLC adenocarcinoma cells (ATCC) and HEK293T human embryonic kidney cells
(provided by Dr. Geoffrey Clark after STR profiling) were maintained in DMEM (Gibco)
supplemented with 10% FBS and 50 µg/ml gentamicin (Gibco). PC9 NSCLC adenocarcinoma cells
(provided by Dr. Levi Beverly after STR profiling) were maintained in RPMI media (Gibco)
supplemented with 10% FBS and 50 µg/ml gentamicin (Gibco). All cells were cultured in humidified
incubators at 37 0C and 5% CO2.
Plasmid construction and mutagenesis
Full-length human PKM2 cDNA was amplified from A549 cells using primers forward:5’CTGGGGATCCATGTCGAAGCCCCATAGTGAAG-3’

and

reverse:5’-GATCGAATTCTCA

CGGCACAGGAACAACACGC-3’ and sub-cloned into the pcDNA 3.1/FLAG vector [FLAG-wildtype (WT) PKM2]. FLAG-PKM2 WT plasmid was used to generate mutant PKM2 expression
constructs using either the QuikChange site-directed mutagenesis kit (Stratagene) or Q5 sitedirected mutagenesis kit (New England Biolabs), respectively. Primers utilized for the PKM2 sitedirected mutagenesis study are listed in Table 1. All plasmid constructs were verified by sequencing
analysis (Eurofins Genomics).
Transient transfection
HEK293T cells were transfected with FLAG-tagged empty vector (FLAG-EV) [FLAG-HApcDNA3.1 (Addgene, # 52535)], PKM2 WT, or mutant PKM2 [MT(1-4)] vectors using jetPEI
(PolyPlus) transfection reagents according to manufacturer’s protocols. Forty-eight hours posttransfection, cells were lysed in IP lysis buffer (Pierce) and co-immunoprecipitation was performed.
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Table 1: PCR primers for the site-directed mutagenesis. Point mutations are indicated in
bold letters and underlined.
Primer ID

Sequence (5’-3’)

MT1-PKM2-F
cagaggctgccatctaccacaggaaattatttgaggaactccgc
MT1-PKM2-R
gcggagttcctcaaataatttcctgtggtagatggcagcctctg
MT2-PKM2-F
ctccgccgcctggcgagccataccagcgaccccac
MT2-PKM2-R
gtggggtcgctggtatggctcgccaggcggcggag
MT3-PKM2-F
gcgagccataccagcgaccccacagaa
MT3-PKM2-R
caggcggacgagttcctcaaataattgcaagtggtag
MT4-PKM2-F
tgaggaactcgtccgcctggcgc
MT4-PKM2-R
aataattgcaagtggtagatggc
K433Q-PKM2-F cgtcctcacccagtctggcag
K433Q-PKM2-R attatggccccactgcag
shRNA-resistant-PSAT1
PSAT1-F
PSAT1-R

Mutagenesis
Kit
QuikChange
mutagenesis
XL kit
Q5
Site-Directed
Mutagenesis

tactgttagagatacaaaaggaattattagactacaaaggagttggcattag
cactgtgcggcagcttggcggg

Generation of stable cell lines
PSAT1 stable knockdown: A549 or PC9 cells were transfected with shRNA (PSAT1 shRNA
or Non-targeted Mammalian Control shRNA) using jetPEI and clonal cells were selected in 1 µg/ml
puromycin.
PSAT1

genetic

knockout:

PC9

cells

were

transfected

with

the

PSAT1

CRISPR/Cas9n(D10A)-Puromycin nickase plasmid using jetPEI. Stably transfected cells were
selected in 1 µg/ml puromycin. To achieve PSAT1 genomic deletion, puromycin selected PC9 cells
were transfected with the PSAT1 CRISPR/Cas9n(D10A)-GFP nickase plasmid. PSAT1 knockout
cells were clonally expanded from GFP-positive cells and validated by immunoblotting. Puromycin
selected cells without GFP-nickase transfection served as control knockout cells.
Ectopic FLAG-tagged PSAT1 expression: PSAT1 cDNA (Forward: 5’-TGGGATCCATGG
ACGCCCCCAGGCAGGTG-3’ and reverse: 5’-TGGAATTCTCATAGCTGATGCATCTCCAA-3’)
was cloned into pcDNA 3.1/FLAG vector. PC9 cells were transfected with FLAG-tagged PSAT1 or
FLAG-EV using jetPEI and selected in 200 µg/ml geneticin (Gibco).
PSAT1 rescue studies: An shRNA-resistant FLAG-tagged PSAT1 expression plasmid was
generated by site-directed mutagenesis (primers listed in Table 1). For these studies, the shRNA-
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resistant FLAG-PSAT1 expression vector was co-transfected with PSAT1 shRNA into parental PC9
cells. Alternatively, PC9 cells were co-transfected with either FLAG-EV and non-targeted shRNA
or PSAT1 shRNA to serve as control and PSAT1-silenced PC9 cells, respectively.

Stably

transfected cells were selected in 200 µg/ml geneticin (Gibco) and 1 µg/ml puromycin (Sigma).
Nuclear

PKM2

overexpression:

CCATGTCGAAGCCCCATAGTGAAG-3’

PKM2

cDNA

(Forward:

and

reverse:

5’-TATTTAGGCGCG

5’-GCCCGTTAATTAATCAC

GGCACAGGAACAACACGC-3’) was subcloned into pcDNA-3xFLAG-NLS vector (Addgene,
#53585).

FLAG-PKM2NLS-K433Q

expression

plasmid

was

generated

by

site-directed

mutagenesis (primers listed in Table 1). All constructs were verified by sequencing analysis.
shPSAT1 PC9 cells were transfected with FLAG-PKM2NLS-WT, FLAG-PKM2NLS-K433Q, or FLAG-EV
using jetPEI. Control PC9 cells were transfected with FLAG-EV only. Stably transfected cells were
selected in 200 µg/ml geneticin and 1 µg/ml puromycin.
FLAG-PKM2 WT or MT3 expression: Stable FLAG-PKM2 WT or MT3 expressing PC9 cells
were generated via transfection and clonal expansion under 200 µg/ml geneticin (Gibco). Transient
knockdown of endogenous PKM2 in these stable cells was performed by transfection with a pool
of

three

siRNA

duplex

ccagatggcaagagggtgatt-3’,

oligonucleotides

against

PKM2

5’-gatcaacgcctcactgaaatt-3’,

and

3’UTR

region

(sense:

5’-

5’-gagcctacctgtatgtcaatt-3’)

(Dharmacon) using jetPEI.
EGF and erlotinib treatment
EGF Treatment: Stable A549 Control and shPSAT1 cells were serum-starved in serumfree DMEM for 24 hours and subsequently treated with 100 ng/ml EGF or vehicle (10mM acetic
acid) for 6 hours. Cells were then collected for subcellular fractionation or co-immunoprecipitation
analysis.
Erlotinib Treatment: Stable PC9 Control and shPSAT1 cells were treated with 1 µM of
erlotinib or vehicle (DMSO) in serum-free RPMI media for 48 hours prior to sub-cellular fractionation
analysis.
Subcellular fractionation
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Cytosolic and nuclear proteins were isolated using the NE-PER kit (Thermo Scientific,
78835). 15 µg of cytoplasmic protein and 25 µg of nuclear protein were used for immunoblotting
analyses.
Co-immunoprecipitation (Co-IP)
One milligram of cell lysate was incubated with 1 µg of anti-PSAT1 or anti-rabbit IgG
(negative control) antibody. Immunoprecipitates were collected using Protein G Dynabeads
(Invitrogen, 10004D) and the immunoprecipitated proteins were analyzed by immunoblot.
For recombinant Co-IP experiments, 50 ng of recombinant PSAT1 protein was mixed with
500 ng of recombinant PKM1 or PKM2 protein. Recombinant PSAT1 in IP lysis buffer alone was
used as a negative control.
Immunoblotting
Protein extracts or co-immunoprecipitations were separated by SDS-PAGE and
transferred to PVDF membrane. Blocked membranes were then incubated with the indicated
primary antibodies. Protein detection was performed using HRP-conjugated secondary antibodies
and visualized by chemiluminescence (GE Healthcare).
Immunofluorescence staining
Cells were plated in 4-well chamber slides, incubated in serum-free media for 24 hours,
and fixed in 4% paraformaldehyde. After blocking, cells were incubated with primary anti-PKM2
and Alexa Fluor 488- conjugated secondary antibodies. Slides were then mounted with SlowFade
Diamond Antifade Mountant with DAPI (S36964) reagent. Images were captured by Olympus FV3000 confocal microscope equipped with Fluoview software under 40X magnification.
Wound-healing assay
All PC9 cell lines were plated at 106 cells/ well in 6 well-plate and grown in complete media
overnight. Experimental conditions for motility assays were used to minimize the contribution of cell
proliferation on wound healing, as described previously (147). After plating, cells were incubated in
serum-free media for 24 hours. Confluent monolayer of cells was then wounded with a pipette tip,
washed three times, and cultured in low serum-RPMI media (1%). Images were captured at 0 and
24 hours and analyzed using Image J software with MRI wound healing tool (148). The migrated
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area was calculated by subtraction of wound area (arbitrary unit) at 24 hours from the initial wound
area.
Transwell migration assay
A549 Control and shPSAT1 stable cell lines were plated at 70% confluency and cultured
in complete media for 24 hours. Cells were then serum-starved for 24 hours and 105 cells were
plated in serum-free media in the Boyden chamber. Serum-free media supplemented with 100
ng/ml EGF or vehicle (10 mM acetic acid) was added to the bottom chamber. After 24-hours, cells
were fixed with 100% ice-cold methanol and non-migrated cells were removed. Migratory cells were
stained with 0.05% crystal violet and washed with ddH20. The area of stained cells was quantified
using Image J threshold tool as described (149).
Pyruvate kinase activity assay
Both A549 and PC9 Control and shPSAT1 stable cells were cultured to 70% confluency in
6 well-plate. Intracellular pyruvate kinase activity was assessed using the Pyruvate Kinase Activity
assay kit (Sigma, MAK072) according to the manufacturer’s protocol.
Computational homology modeling of PKM1 and PKM2
The human PKM1 sequence was obtained from the PKM1 crystal structure (Protein Data
Bank entry 3SRF) and was mapped to the human PKM2 structure (Protein Bank entry 4FXJ) using
the Prime-based Homology Modeling Module of the Schrödinger Software Suite (150). The image
was created within Schrödinger Maestro with the sequence differences between PKM1 and PKM2
identified.
Bioinformatic analysis of PSAT1 in EGFR mutant lung cancers:
The GSE32863, GSE75037, GSE31548, GSE31210, and GSE11969 data sets
encompassing gene expression analysis from EGFR mutant lung cancer with clinical information
were downloaded from the GEO database through using BRB-ArrayTool software (151). PSAT1
expression (probe IDs: ILMN_1692938 for GSE32863 and GSE75037, 223062_s_at for GSE31210
and GSE31548, and 5144 for GSE11969) was retrieved from EGFR mutant tumor and normal lung
specimens with clinical information. Differential expression analyses were carried out for tumor vs.
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normal and stage II-III vs. stage I, while Kaplan-Meier analyses were performed for overall survival
and relapse-free survival rates on the indicated data sets.
Statistical analysis
All data were statistically analyzed using Prism 8 software (GraphPad Software). Statistical
significances were assessed based on the number of groups with one or more independent
variables. Paired t-tests were used for the analysis of two groups, with the exception of an unpaired
t-test for the pyruvate kinase assay. While one-way ANOVA with Tukey's multiple comparison test
for three groups was performed for PC9 cell variants, two-way ANOVA with Tukey's multiple
comparison test was used for A549 cell variants with or without EGF treatment. Experimental
replicates for each analysis are stated within the respective figure legend. Values of p< 0.05 were
considered statistically significant.

39

Results
PKM2 is a novel binding partner of PSAT1
Non-canonical functions of metabolic enzymes that directly involve protein-protein
interactions have previously been reported in promoting tumorigenesis (109, 152). To determine
PSAT1-associating proteins, we used a GST-PSAT1 pull-down assay coupled to LC-MS/MS
analysis (Fig. 6A). Among the resolved proteins, we identified pyruvate kinase M (PKM) with
approximately 22% sequence coverage (Fig. 6B). PKM1 and PKM2 are two alternatively spliced
isoforms of the PKM gene and exhibit differential enzymatic properties (153). Utilizing coimmunoprecipitation (co-IP) analysis encompassing only recombinant PKM1, PKM2, and PSAT1,
we found that PSAT1 directly binds to the PKM2 isoform (Fig. 6C). Thus, these results identify
PKM2 as a novel direct binding partner of PSAT1.
Based on this interaction, we hypothesized that a PKM2-specific region may contribute to
PSAT1 association. Three-dimensional modeling of human PKM1 and PKM2 demonstrate that
they have 95.8 % sequence homology and have the same overall structure. As depicted in Figure
7A, an isoform-specific region (cyan) is localized to a loop structure that lies towards the exterior of
the monomer. We mutated amino acid residues in wild-type (WT) PKM2 to the corresponding
PKM1 residues by site-directed mutagenesis (Fig. 7A, mutations highlighted in red). Co-IP analysis
involving FLAG-tagged PKM2 WT and mutant (MT[1-4]) proteins revealed that mutations in MT 1,
2, & 4 did not substantially affect the interaction with PSAT1 (Fig. 7B). However, the amino acid
changes within MT3-PKM2 that are inclusive of mutations in both MT 2 and 4 strongly reduced
binding to endogenous PSAT1. Together, the recombinant co-IP and mutational analysis
demonstrate a specific PSAT1:PKM2 interaction.
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A

B

C

Figure 6. PKM2 is a novel binding partner of PSAT1. A) Silver stain of GST-PSAT1
purified proteins from A549 whole cell lysates. * denotes residual GST-PSAT1 from
column purification; Denotes gel slice encompassing PKM. B) Primary amino acid
sequence of human PKM. MS identified peptides of PKM are highlighted in red. Black
labeled sequences belong to common regions of both PKM1 and PKM2 isoforms and
green labeled sequences identify isoform-specificity. C) Co-IP of recombinant (rec-)
PSAT1 and PKM1 or PKM2. Immunocomplexes were precipitated using anti-PSAT1
antibody and analyzed by immunoblot using anti-PKM1 and anti-PKM2 antibody.
RecPKM1 and recPKM2 were used as controls showing antibody specificity and PSAT1
alone was used as IP control. Shown are representative images from two separate
experiments.
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A

B

Figure 7. Mutations within an isoform-specific region of PKM2 weakens the PSAT1
interaction. A) Schematic representation of PKM2 specific mutations generated for analysis
of PSAT1:PKM2 association. Ribbon representation of the structure of PKM2 colored by
PKM1 sequence homology (right panel). Identical regions are shown in purple and
divergent regions in cyan. Left panel depicts site directed mutagenesis of amino acids (MT14, highlighted in red) in the PKM2 specific region (denoted in white box). B) FLAG-PKM2
wild-type (WT), mutants (MT1-4) and FLAG-EV (-) were expressed in HEK293T cells.
Endogenous PSAT1 protein complexes were immunoprecipitated and association of PKM2
was assessed by immunoblot. Similar expression of FLAG-PKM2 variants is shown by
immunoblot of FLAG fusion proteins from protein lysate input with β-actin used a protein
loading control. Shown are representative images from three separate experiments. (-)
denotes empty vector.
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Suppression of PSAT1 in NSCLC cancer cells does not alter PKM2 expression or pyruvate
kinase activity
Previously, the pyruvate kinase activity of PKM2 has been metabolically linked to the serine
biosynthetic pathway in human cancers (52, 57, 61, 62). Our pull-down and recombinant protein
association studies now suggest that these pathways might also be connected via protein:protein
interactions in tumor cells. Co-IP analysis demonstrated an endogenous interaction between
PSAT1 and PKM2 in two separate NSCLC cell models (Fig. 8).
To investigate the functional significance of this PSAT1 and PKM2 interaction, PSAT1
expression was stably silenced in PC9 and A549 cells (Fig. 9A). Given the metabolic cross-talk
between the glycolytic and serine synthetic pathways (52, 57, 61) and this new PSAT1:PKM2
association, we questioned whether loss of PSAT1 may modulate the metabolic activity of PKM2.
As shown in Figure 9B, PSAT1 depletion did not affect pyruvate kinase activity in either cell line.
This was not due to altered PKM2 or PKM1 as analysis of PKM isoform expression found no change
between control and shPSAT1 cells in both A549 and PC9 cells (Fig. 9C). Taken together, we
conclude that while a physiological interaction between PSAT1 and PKM2 exists, suppression of
PSAT1 expression fails to alter pyruvate kinase activity and expression of PKM2 in these NSCLC
cell lines, indicating that this interaction may be dispensable for cellular pyruvate kinase activity.
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Figure 8. PSAT1 associates with endogenous PKM2 in NSCLC cells. Co-IP of PSAT1
and PKM2 in A549 and PC9 NSCLC cells. PSAT1- specific immunocomplexes were
precipitated using anti-PSAT1 from whole cell lysate and analyzed for PKM2 by immunoblot
with anti-PKM2 antibody. Shown are representative images from three separate
experiments.
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A

B

C

Figure 9. Loss of PSAT1 does not alter pyruvate kinase activity and expression. A)
Loss of PSAT1 expression in A549 and PC9 cells stably expressing PSAT1-specific
shRNA.

PSAT1 expression was determined from whole cell lysates from control or

shPSAT1 expressing cells by immunoblot using anti-PSAT1 and anti-α-Tubulin (loading
control). B) Intracellular pyruvate kinase activity was determined in cell lysates from A549
or PC9 cells with or without PSAT1 expression. Data is represented as relative pyruvate
kinase activity (control cells set to 1) and shown are the mean  S.D from four independent
experiments. C) Immunoblot analysis of PKM1 or PKM2 expression in whole cell lysates
from control or PSAT1 silenced A549 and PC9 cells. Recombinant human PKM1 and
PKM2 proteins were used as positive control for the specificity of antibodies and β-Actin
for loading control. Shown are representative images from two separate experiments
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Silencing of PSAT1 suppresses the nuclear localization of PKM2 in EGFR activated NSCLC
cells
As recent studies have demonstrated EGFR-mediated nuclear localization of PKM2 (113,
114, 154), we examined whether PSAT1 may alter PKM2 nuclear localization under EGFR
activation in NSCLC cells. Subcellular fractionation confirmed that the nuclear localization of PKM2
in EGFR-mutant PC9 cells was blocked with the EGFR-TKI, erlotinib (Fig. 10A). Importantly,
cellular fractionation and immunofluorescence analysis found that loss of PSAT1 expression by
either stable shRNA or CRISPR-mediated knock-out diminished PKM2 translocation under EGFRactivation (Figs. 10A and B and 11). To complement these losses of function studies, conversely,
overexpression of FLAG-tagged PSAT1 (Fig. 12A) in parental PC9 cells resulted in higher levels
of nuclear PKM2 (Fig. 12B). Unexpectedly, PSAT1 was also found within the nuclear compartment
within PC9 cells, which was abrogated with erlotinib treatment and enhanced with FLAG-tagged
PSAT1 overexpression (Fig. 10A, 11 and 12B).
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B

Figure 10. Silencing of PSAT1 suppresses the nuclear localization of PKM2 in EGFR
mutant PC9 cells. A) EGFR-mutant PC9 cells stably expressing control or PSAT1 shRNA
were treated with 1 µM of erlotinib for 48 hrs. Cytoplasmic and nuclear fractions were
examined by immunoblot analysis using anti-PKM2 and anti-PSAT1 antibodies. OCT1 and
α-tubulin served as loading controls for nuclear and cytoplasmic compartments,
respectively. Shown are representative images from three separate experiments. B)
Nuclear localization of PKM2 was examined in serum-starved PC9 cells expressing control
or PSAT1 shRNA by confocal microscopy. Representative Immunofluorescence image
with anti-PKM2 antibody (green) and DAPI nuclei staining (blue). Arrowheads indicate
nuclear PKM2 staining.
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Figure 11. CRISPR-mediated PSAT1 knockout reduces PKM2 nuclear localization in
EGFR mutant PC9 cells. Immunoblot analysis of PKM2 and PSAT1 localization after PSAT1
deletion. Cytoplasmic and nuclear fractions from Control and PSAT1 KO PC9 cells were
analyzed using anti-PKM2 antibody or anti-PSAT1 antibody. OCT1 and α-tubulin served as
loading controls for nuclear and cytoplasmic compartments, respectively. Shown are
representative images from three independent experiments.
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B

Figure 12. Ectopic expression of PSAT1 induces PKM2 nuclear localization in EGFR
mutant PC9 cells. A) Immunoblot analysis of FLAG-PSAT1 expression in PC9 cells.
Endogenous and tagged PSAT1 was analyzed using anti-PSAT1 antibody in lysates from
PC9 cells expressing empty vector (FLAG-EV) or vector encoding FLAG-PSAT1. α-Tubulin
expression was used for loading control. Shown are representative images from three
independent experiments. B) PKM2 localization in PC9 cells ectopically FLAG-EV or
FLAG-PSAT1. Cytoplasmic and nuclear fractions from FLAG-EV and FLAG-PSAT1
expressing cells were analyzed using anti-PKM2 antibody. OCT1 and α-tubulin served as
loading controls for nuclear and cytoplasmic compartments, respectively. Shown are
representative images from three independent experiments.
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We further substantiated these findings in A549 cells harboring wild-type EGFR through
EGF stimulation (155, 156). Fractionation analysis revealed enhanced nuclear translocation of
PKM2 in EGF-stimulated A549 cells compared to untreated control cells, while the loss of PSAT1
significantly inhibited induced PKM2 nuclear translocation (Fig. 13). Consistent with the findings in
PC9 cells, PSAT1 nuclear localization was also observed in EGF-stimulated A549 cells. We then
determined whether EGF stimulation alters the PSAT1:PKM2 interaction in A549 cells as a means
of promoting enhanced nuclear localization. Co-IP analysis from A549 stimulated with or without
EGF found similar PSAT1:PKM2 interactions and the level of PKM2 did not significantly change in
response to EGF stimulation (Fig. 14).
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Figure 13. Loss of PSAT1 abrogates EGF-induced nuclear localization of PKM2 in
EGFR-WT A549 cells. Serum-starved A549 cells (EGFR-wild-type) stably expressing
control or PSAT1 shRNA were treated with or without EGF (100 ng/ml). Cytoplasmic and
nuclear fractions were prepared and PKM2 and PSAT1 localization was analyzed by
immunoblot. OCT1 and α-tubulin served as loading controls for nuclear and cytoplasmic
compartments, respectively. Shown are representative images from three separate
experiments.
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Figure 14. EGF-stimulation does not alter the PSAT1:PKM2 association. Serumstarved A549 cells were treated without or with EGF (100 ng/ml). Shown is a
representative co-IP (n = 2) performed using anti-PSAT1 or IgG antibody. PKM2 and
PSAT1 were analyzed by immunoblot using anti-PKM2 or PSAT1 antibodies.
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The observation that both PSAT1 and PKM2 translocate to the nucleus upon EGFRactivation prompted us to investigate the putative involvement of direct protein-protein interaction
in their nuclear localization. FLAG-tagged PKM2 WT or MT3, which has diminished PSAT1
association (Fig. 7B), were stably expressed in endogenous PKM2 depleted PC9 cells. We found
that both PKM2 forms were able to localize in the nucleus (Fig. 15). While this may suggest that a
direct interaction may not be essential for PSAT1’s function in promoting nuclear PKM2, the direct
association of PKM2 with these fusion proteins has not yet been defined in the PC9 cells. Further,
the co-IP studies in the HEK293T cells showed residual binding of PKM2 MT3 to PSAT1, which
may in itself be sufficient in promoting nuclear localization.
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Figure 15. A PSAT1-interaction deficient PKM2 mutant is still able to localize to the
nucleus in PC9 cells. Immunoblot analysis of FLAG-PKM2 WT or MT3 localization in
PC9 cells stably expressing empty vector (-), FLAG-PKM2 WT, or FLAG-PKM2 MT3.
Endogenous PKM2 was silenced via siRNA prior to cytoplasmic and nuclear fractionation
of the indicated cell lines. OCT1 and α-tubulin served as loading controls for nuclear and
cytoplasmic compartments, respectively. Shown are representative images from three
independent experiments. indicates FLAG-tagged PKM2, * indicates non-specific
band.
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Loss of PSAT1 suppresses migration of EGFR-mutant and EGF-induced EGFR-WT lung
cancer cells
The oncogenic function of PSAT1 has been investigated in many tumor types and found
to play a role in proliferation, migration, and chemo-resistance (1, 43, 71, 74, 77, 79, 81), yet it
remains elusive whether PSAT1 may contribute to the cellular response to specific oncogenic
signaling, particularly EGFR. Since previous studies have shown that EGF exposure selectively
induces cell migration in A549 cells without affecting proliferation (155, 156), we investigated the
role of PSAT1 in cell motility in EGFR-activated NSCLC cells. We found that loss of PSAT1
significantly decreased EGFR-mutant PC9 cell motility (Fig. 16 and 17) and observed no impact on
cell proliferation with stable shRNA-mediated silencing under these experimental conditions (Fig.
18). In addition, PSAT1 suppression completely inhibited EGF-induced cell migration in A549 cells
(Fig. 19).

55

Figure 16. Loss of PSAT1 decreases cell motility in EGFR mutant PC9 cells. Wound
healing assay of serum-starved PC9 cells expressing control or PSAT1-specific shRNA.
Representative images at 0 hr and 24 hr with migrating cells demarcated by white
continuous lines. Data is presented as migrated area after 24 hours and shown is mean
 SE from three independent experiments. * p < 0.005. A.U.: arbitrary unit.
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Figure 17. CRISPR-mediated PSAT1 knockout decreases PC9 cell motility. Wound
healing assay of serum-starved Control and PSAT1 KO PC9 cells. Shown are
representative images at 0 hr and 24 hr with migrating cells demarcated by white
continuous lines. Data is presented as mean ± SE migrated area after 24 hours from
three independent experiments. *, p<0.05. A.U.: arbitrary unit.
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Figure 18. Stable PSAT1 suppression does not impact PC9 cell proliferation under
medium conditions and timing used within cell migration assays. PC9 cells (plated at
low density -10,000 cells) were serum starved for 24-hours prior to addition of 1% serum.
Proliferation was monitored by cell enumeration at the indicated time points. Shown are
mean  SE from two independent experiments. No effect on cell proliferation was observed
at 24 hours and PSAT1 loss had moderate impact at three and four days.
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Figure 19. Loss of PSAT1 decreases cell migration in EGF-stimulated A549 cells.
Boyden chamber migration assay on serum-starved A549 cells expressing control or
PSAT1 shRNA. 100 ng/ml EGF serum-free media was used as chemoattractant and
migrated cells were fixed and stained with crystal violet after 24hr. Shown are
representative images of migrated cells and quantification is demonstrated as mean 
SE of % migration area from three independent experiments. *, p=0.0001. N.S: not
significant.
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To demonstrate PSAT1 specificity, we restored expression in silenced PC9 cells (Fig. 20).
Re-expression of PSAT1 rescued not only nuclear localization of PKM2 (Fig. 20A and B) but also
cell migration (Fig. 21). Increased cell migration upon ectopic PSAT1 overexpression further
corroborates these findings (Fig. 22). These results demonstrate a role for PSAT1 in PKM2 nuclear
localization and cell migration in these NSCLC models.
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A

B

Figure 20. Re-expression of PSAT1 restores the nuclear localization of PKM2 in
silenced PC9 cells. A) Immunoblot analysis of cytoplasmic and nuclear fractions from
Control-EV, shPSAT1-EV and shPSAT1-FLAG-PSAT1 PC9 cells using anti-PKM2 and
anti-PSAT1 antibodies. OCT1 and α-tubulin served as loading controls for nuclear and
cytoplasmic compartments, respectively. Shown are representative images from three
independent experiments. B) Immunofluorescence analysis of PKM2 localization in
Control-EV, shPSAT1-EV and shPSAT1-FLAG-PSAT1 PC9 cells by confocal microscopy.
Immunofluorescence image with anti-PKM2 antibody (green) and DAPI nuclei staining
(blue). Arrowheads indicate nuclear PKM2 staining. EV: Empty Vector.
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Figure 21. Re-expression of PSAT1 restores cell migration in silenced PC9 cells.
Wound healing assay of Control-EV, shPSAT1-EV, and shPSAT1-FLAG-PSAT1 PC9 cells.
Shown are representative images at 0 hr and 24 hr with migrating cells demarcated by
white continuous lines. Data is presented as mean  SE migrated area after 24 hours from
three independent experiments. **, p<0.005 and *, p<0.05. EV: Empty Vector, A.U.:
arbitrary unit.
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Figure 22. Ectopic expression of PSAT1 induces cell migration in EGFR mutant PC9
cells. Wound healing assay of serum-starved PC9 cells expressing FLAG-EV or FLAGPSAT1. Shown are representative images at 0 hr and 24 hr with migrating cells demarcated
by white continuous lines. Data is presented as mean  SE migrated area after 24 hours
from three independent experiments. *, p<0.05. EV: Empty Vector, A.U.: arbitrary unit.
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Re-expression of nuclear-localized acetyl-mimetic (K433Q) PKM2 partially restores the
migration defect due to the loss of PSAT1 in EGFR mutant cells
We then assessed whether nuclear PKM2 may be required for the PSAT1-mediated cell
migration in EGFR-mutant cells. Nuclear PKM2 was reconstituted via stable expression of FLAGtagged PKM2 harboring a nuclear localization signal (FLAG-PKM2NLS-WT) in PC9 cells (Fig. 23A).
However, the re-expression of nuclear PKM2 did not restore wound healing in PSAT1 depleted
cells (Fig. 23B).
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Figure 23. Re-expression of nuclear-localized wild-type PKM2 does not rescue the
migration defect due to the loss of PSAT1 in EGFR mutant PC9 cells. A) Immunoblot
analysis of cytoplasmic and nuclear fractions from Control-EV, shPSAT1-EV, and
shPSAT1-PKM2NLS-WT expressing cells using anti-PKM2 and anti-PSAT1 antibodies. OCT1
and α-tubulin served as loading controls for nuclear and cytoplasmic compartments,
respectively. Shown are representative images from three independent experiments. B)
Wound healing assay of serum-starved PC9 cells expressing Control-EV, shPSAT1-EV,
and shPSAT1-PKM2NLS-WT. Shown are representative images at 0 hr and 24 hr with
migrating cells demarcated by white continuous lines. Data is presented as mean ± SE
migrated area after 24 hours from three independent experiments. *, p<0.0001. NS: not
significant, A.U.: arbitrary unit, and NLS: nuclear localization signal.
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PKM2 can be acetylated at K433 upon EGF stimulation, which localizes in the nucleus
and exhibits higher protein kinase activity compared to wild-type PKM2 (110). Consistent with this
result, SIRT6-mediated deacetylation of K433 results in the export of PKM2 from the nucleus,
suggesting that acetylation of PKM2 at K433 is critical for nuclear localization and function (157).
For this, we stably expressed acetyl-mimetic nuclear PKM2 (FLAG-PKM2NLS-K433Q) in cells lacking
PSAT1. Fractionation analysis confirmed reconstitution of acetyl-mimetic nuclear PKM2 (Fig. 24A).
Unlike wild-type PKM2, nuclear acetyl-mimetic PKM2 significantly rescued (41%) PC9 cell motility
in the absence of PSAT1 (Fig. 24B). Together, these results suggest that PSAT1 promotes EGFRstimulated PKM2 translocation, potentially through regulating PKM2 post-translation modifications.
This contributes, in part, to PSAT1 mediated cell motility within these EGFR-activated NSCLC cells.
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Figure 24. Re-expression of nuclear-localized acetyl-mimetic (K433Q) PKM2 partially
rescues the migration defect due to the loss of PSAT1 in EGFR mutant PC9 cells. A)
Immunoblot analysis of cytoplasmic and nuclear fractions from Control-EV, shPSAT1-EV,
and shPSAT1-PKM2NLS-K433Q expressing cells using anti-PKM2 and anti-PSAT1
antibodies. OCT1 and α-tubulin served as loading controls for nuclear and cytoplasmic
compartments, respectively. Shown are representative images from three independent
experiments. B) Wound healing assay of serum-starved PC9 cells expressing Control-EV,
shPSAT1-EV, and shPSAT1-PKM2NLS-K433Q. Shown are representative images at 0 hr and
24 hr with migrating cells demarcated by white continuous lines. Data is presented as mean
± SE migrated area after 24 hours from three independent experiments. **, p<0.0001 and
*, p<0.05. A.U.: arbitrary unit, and NLS: nuclear localization signal.
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PSAT1 expression negatively correlates with survival outcomes in EGFR-mutant NSCLC
We next sought to investigate the clinical relevance of PSAT1 in EGFR mutant lung cancer
using microarray datasets and corresponding clinical outcomes from EGFR mutant lung tumors.
Expression analysis found elevated PSAT1 expression in both paired and unpaired EGFR mutant
lung tumors compared with normal lung (Fig. 25). Furthermore, late-stage EGFR mutant lung
tumors tended to exhibit increased PSAT1 expression than early-stage tumors (Fig. 26). Finally,
Kaplan-Meier analysis correlated high PSAT1 expression to poorer relapse-free and overall
survival rates in this patient population (Fig. 27). These findings suggest that high PSAT1
expression negatively impacts clinical outcomes in EGFR mutant lung cancer.
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Figure 25. PSAT1 is elevated EGFR-mutant lung cancer compared to normal lung.
Expression analysis of PSAT1 in EGFR mutant lung tumors compared to normal lung in
paired (GSE32863 and GSE75037) and unpaired (GSE31548 and GSE31210) datasets.
Paired (GSE32863 and GSE75037) and unpaired (GSE31548 and GSE31210) t-tests
were performed to determine statistical significance.
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Figure 26. PSAT1 is increased in later stages of EGFR-mutant lung cancer. Expression
analysis of PSAT1 in late stage (Stage II and/ or stage III) compared with early stage (Stage
I) EGFR mutant lung tumors. Data was statistically evaluated using unpaired t-test.
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Figure 27. Elevated PSAT1 is associated with poor outcomes in EGFR-mutant
NSCLC. Kaplan-Meier analysis was performed to assess the correlation of PSAT1
expression with A) overall survival and B) relapse-free survival rates in EGFR mutant lung
cancer patients.
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Discussion
Elevated PSAT1, along with other enzymes within the SSP, has previously been reported
in lung cancer (1, 42, 45). Notably, tumor-initiating cells display increased expression of PSAT1,
further emphasizing the functional significance of PSAT1 in lung cancer progression (86). While
the role of PSAT1 has been investigated in the context of metabolic function, the potential for an
alternative role in tumorigenesis remains unclear. Recent discoveries of multifunctionality of
metabolic enzymes in tumorigenic processes led us to explore a putative non-canonical function of
PSAT1 involved in lung cancer progression (104, 152). In the present study, we identified an
interaction between PSAT1 and PKM2 and a need for nuclear PKM2 in PSAT1-driven motility of
EGFR-activated NSCLC cells.
PKM2 functions as the predominant pyruvate kinase in many tumor types and promotes
growth by various different mechanisms, including regulating anabolic reactions (153). For
example, flux through serine biosynthesis is partially controlled through a feedback loop involving
PKM2 activity (52, 57). In line with this, small-molecule activators of PKM2 predominantly exert
their anti-tumorigenic effect under serine deprivation conditions in vitro (60, 61). As these findings
indicate a metabolic cross-talk between PKM2 activity and serine, we speculated that depletion of
PSAT1 in the cells may alter intracellular pyruvate kinase activity of PKM2 either through reduced
serine levels or potentially through disruption of the protein:protein interaction. However, both A549
and PC9 cells did not display a significant change in PKM2 expression or activity in response to
PSAT1 silencing, suggesting that PSAT1 association does not influence intracellular PKM2 activity.
As our studies were performed in a serine-proficient medium, we postulate that serine import may
have sustained intracellular serine levels, which may have contributed to the lack of effect on
pyruvate kinase activity in the absence of PSAT1.
Among the oncogenic-drivers of lung adenocarcinoma, activating mutations within the
EGFR tyrosine kinase domains account for approximately 17% of these diagnoses (90). Like GBM,
nuclear PKM2 has been detected in EGFR mutant NSCLC cancer cells but not in EGFR wild-type
NSCLC cells (113, 130, 154). While nuclear PKM2 mediates EGFR-induced proliferation, epithelialmesenchymal transition (EMT), migration, and invasion in GBM, HCC, and nasopharyngeal
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carcinoma cells, EGFR-mediated nuclear function of PKM2 in lung cancer remains elusive, despite
a finding as a predictor for response to PARP inhibitor treatment in EGFR-mutant NSCLC cells
(113, 154, 158-160). In addition, prior work has also demonstrated that EGF-stimulation promotes
cell migration in A549 NSCLC cells that express wild-type EGFR (155, 156). Based on these
studies, we speculate that PSAT1 might participate in cell migration under EGFR-activation through
facilitating nuclear localization of PKM2. While suppression of PSAT1 decreased EGFR-induced
nuclear localization of PKM2, nuclear PKM2 was rescued upon PSAT1 restoration or elevated in
ectopic FLAG-PSAT1 overexpressing PC9 cells, implicating a requirement for PSAT1 for PKM2’s
translocation. Accordingly, cell migration decreased upon PSAT1 suppression and increased when
PSAT1 was expressed. Various signals, including EGF, can stimulate PKM2 acetylation at K433,
which is required for nuclear function and contributes to tumor progression (110, 157). Consistent
with these previous studies, we found that restoration of acetyl-mimetic nuclear PKM2, but not wildtype PKM2, partially reverts the migratory defect due to the suppression of PSAT1. Therefore, our
results indicate a correlation between PSAT1-mediated cell migration and nuclear localization of
PKM2 upon EGFR-activation.
Although we are able to demonstrate an interaction between PSAT1 and PKM2, our
findings yield new unanswered questions. For instance, it is still unclear how PSAT1 may regulate
the nuclear localization of PKM2. Similar to PKM2, we also observed EGFR-activation dependent
nuclear translocation of PSAT1. However, the requirement of this interaction for nuclear localization
is still unclear as a PKM2 mutant that exhibits reduced binding with PSAT1 was still able to localize
to the nuclear compartment. Alternatively, PSAT1 may be an essential mediator of EGFR-signaling
to PKM2. Upon EGFR activation, cytosolic to nuclear translocation of PKM2 requires multiple steps,
including phosphorylation by ERK2, isomerization by PIN1, and then importin α5 mediated nuclear
import (114). Subsequently, nuclear retention of PKM2 is aided through binding to poly ADP-ribose
(PAR) (154). Given the complexity of nuclear localization of PKM2 mentioned above, it is worth
identifying which step or steps are influenced by PSAT1, which is the focus of on-going studies.
The subcellular location in which PKM2 is acetylated by p300 at K433 remains obscure
despite the acetylated form being localized in the nucleus and deacetylation resulting in nuclear
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export (110, 157). Therefore, it is intriguing whether PSAT1 loss inhibits the nuclear localization of
PKM2 by disrupting its acetylation. As p300 acetylates PKM2 in response to oncogenic stimuli,
including EGF (110), we postulate that PSAT1 depletion may disrupt the p300:PKM2 interaction or
alter EGFR-downstream signaling pathways that regulate p300 activity (161). While nuclear PKM2
is required for EGF-involved EMT-mediated cell migration in HCC, oral squamous carcinoma, and
colon cancer, further work is also needed to fully define the mechanisms by which nuclear PKM2
promotes cell motility under EGFR-activation in NSCLC (158, 162, 163).
The partial rescue observed within the PKM2 expression studies indicates that other
PSAT1 activities contribute to EGFR-activated NSCLC motility independent of nuclear PKM2,
which may include putative nuclear-specific PSAT1 function(s). As the metabolic function of PSAT1
has not yet been thoroughly examined in this context, its enzymatic activity on cell migration and
nuclear localization of itself and PKM2 needs further investigation, potentially through the use of
metabolic deficient PSAT1 mutants. In summary, we have identified PKM2 as a new PSAT1
associating protein in NSCLC cells. Whereas PSAT1 appears to be dispensable for PKM2’s
pyruvate kinase activity, it is essential for PKM2 nuclear localization in EGFR-activated NSCLC
cells. This supports, in part, PSAT1’s ability to promote cell migration under EGFR signaling, which
may be a contributing determinant for its negative correlation with patient outcomes in EGFRmutant NSCLC.
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CHAPTER 3
DELINEATING THE FUNCTIONAL LINK BETWEEN A PSAT1-ASSOCIATED GENE
EXPRESSION SIGNATURE AND EGFR-MUTANT LUNG CANCER
Introduction
Genome-wide gene expression profiling has become routine since the discovery of
microarray technologies and the completion of the human genome project. Gene expression
patterns have allowed for determining the mechanisms that drive diseases, identifying disease subtypes, predicting disease progression, and providing functional information about the differentially
expressed genes that can be grouped into functional pathways (164, 165). More recently, RNA
sequencing (RNA-seq) has taken the place of microarrays as the cost of sequencing has fallen.
This change has also facilitated the discovery of new fusion transcripts involved in tumorigenesis
(166).
Analysis of these technologies has also required the development of bioinformatics tools
to help researchers handle these large datasets and extract any biological information. MSigDB
and WebGestalt are both well-known web-based integrated data-mining systems that can explore
large gene sets (167, 168). They are user-friendly bioinformatics tools that help users in the
management, information retrieval, organization, visualization, and statistical analysis of gene sets.
The

Gene Expression Omnibus (GEO) database was founded to serve as a public

repository for high-throughput gene expression and other functional genomics datasets (169).
Researchers can easily access either the raw or processed data that may benefit their own studies.
Furthermore, biostatisticians of the Biometric Research Branch of the National Cancer Institute
have developed the BRB-ArrayTools software package, which is non-commercial and user-friendly
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sequence profiling analysis tool (151). In addition to the normalization of the genomics data, it has
many plugins to help in performing further analysis. For example, these include class comparison
analysis for determining differentially expressed genes between groups as well as survival risk
prediction tools for identifying gene signatures that may predict patients outcomes (170). In
addition, it has many statistical tools such as cluster, ANOVA, and time-series analysis.
In the previous chapter, we demonstrated a requirement for PSAT1 in EGFR-mediated cell
migration. The partial rescue in cell migration with the restoration of nuclear PKM2 implies the
potential presence of other PSAT1-dependent mechanisms. As we also found nuclear localization
of PSAT1 upon EGFR activation, this prompted us to carry out genome-wide RNA-seq expression
profiling under PSAT1 loss. Through analysis of differentially expressed genes, our intent was to
identify other unknown mechanisms for PSAT1 in contributing to tumorigenesis. Further, to take
advantage of the many genome-wide datasets focused on EGFR mutant lung cancer, we also
compared our PSAT1-associated genes with differentially expressed genes in EGFR mutant lung
tumors using the BRB-Array tools. This was done with the intent of identifying an EGFR related
PSAT1 gene signature, which may have potential clinical application.
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Methods and Materials
Reagents and antibodies
Antibodies against PKM2 (4053), β-catenin (8480), OCT1(8157), and 𝑎-Tubulin (3873)
were obtained from Cell Signaling Technology. Anti-PSAT1 (10501-1-AP) antibody was purchased
from Proteintech Group Inc. β-actin (A2228), 100x EmbryoMax Nucleosides (ES-008-D), and
Dimethyl 2-oxoglutarate(349631) were obtained from Sigma.

pGL4.49[luc2P/TCF-LEF/Hygro]

Vector (E4611) and Dual-Luciferase Reporter Assay System (E1960) were purchased from
Promega. Difco Noble Agar (214220) from BD Bioscience and 100X NEAA (non-essential amino
acid) (25-025) were purchased from Corning.
Cell culture
Generation of stable PC9 cells (Control and shPSAT1 PC9, Control-EV, shPSAT1-EV,
shPSAT1-FLAG-PSAT1, and shPSAT1-PKM2NLS-K433Q) were previously discussed in chapter 2.
Control and shPSAT1 PC9 cells were maintained in RPMI media (Gibco) supplemented with 10%
FBS, 50 µg/ml gentamicin (Gibco), and 1 µg/ml puromycin. Control-EV, shPSAT1-EV, shPSAT1FLAG-PSAT1, and shPSAT1-PKM2NLS-K433Q PC9 cells were maintained in RPMI media (Gibco)
supplemented with 10% FBS, 50 µg/ml gentamicin (Gibco), 1µg/ml puromycin, and 200ug/ml
geneticin. All cells were cultured in humidified incubators at 37C and 5% CO2.
RNA isolation and reverse transcription
RNA was harvested with RNeasy Mini Kit according to the manufacturer’s instructions
(Qiagen, 74106). RNA quality and concentration were measured with Nanodrop RNA 6000 nanoassays (for reverse transcription PCR (RT- PCR)). 2 µg of isolated total RNA was reverse
transcribed

by

High-Capacity

RNA-to-cDNA

according

to

manufacturer’s

instructions

(ThermoFisher Sci., 4387406). The cDNA sample was diluted by adding 60 μl Nuclease-free water
to make an estimated final concentration of 25 ng/μl.
Real-time PCR for mRNA
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10 µl of reaction mix was prepared by adding 1 µl of cDNA. 0.5 µl target probe (FAM
conjugated), 0.5 µl of ACTB( VIC), and 5 ul of TaqMan Fast Advanced Master Mix (Thermo Fischer
Sci, 4444557) and reactions were carried out according to Taqman Fast Reaction Protocol using
AB StepOnePlus Real-Time PCR System (Applied Biosystems). Data were analyzed using Ct
method and β-actin (ACTB) was used as a reference gene. The list of Real-time PCR Taqman
probes is presented in Table 2.

Table 2. Taqman probe list
Gene Name
# PROBE
USP14
Hs00193036_m1
VAPA
Hs00427749_m1
NDUFV2
Hs00221478_m1
TYMS
Hs00426586_m1
METTL4
Hs01559838_m1
SEH1L
Hs01031566_m1
IMPA2
Hs00274110_m1
MYL12B
Hs01050560_m1
S100A4
Hs00243202_m1
TMSB4X
Hs03407480_gH
FHOD1
Hs01077922_m1
ACTB
Hs01060665_g1

Soft agar assay and metabolite supplementation
For both Control and shPSAT1 PC9 cells, 2 assays for each of the 8 conditions were
prepared: No supplement (-); NEAA; Nucleoside; 500 µM α-ketoglutarate (α-KG); NEAA + 500 µM
α-KG; NEAA + Nucleoside; Nucleoside + 500 µM α-KG; ALL (NEAA+ Nucleoside+ 500 µM α-KG).
Dimethyl 2-oxoglutarate served as α-KG supplement.
i.

Base agar: 18 ml of warmed 2% noble agar were mixed with 42 ml of warmed 10% FBS
media. 3ml of the mixture was then added to individual 6-cm cell culture plates and
incubated at room temperature until solidified.

ii.

Top agar: (Each condition, 2 plates) 1.3 ml of warmed 2% noble agar were mixed with 8 ml
of warmed 10% FBS media containing 3000 cells and supplemented with the indicated
metabolite(s). 3 ml were then added to the top of the base agar and incubated at room
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temperature until solidified. Cells were cultured in humidified incubators at 370 C and 5%
CO2 for 21 days and maintained with feeder layers every 3-4 days, as described below.
iii.

Maintenance of culture with feeding media (4 plates/metabolite addition): 1.25 ml of warmed
2% noble agar were mixed with 8.75 ml of warmed 10% FBS media supplemented with the
indicated metabolite(s). Cells were then fed with 1.5 ml of feeding media every 3-4 days
during 21-day incubation. At the end of the study, whole plate images were captured, and
colonies were counted via Image J cell counting tool.

Soft agar assay for rescue study
In both PSAT1 and nuclear PKM2 rescue study, 4 plates were prepared for each condition
(Control-EV, shPSAT1-EV, shPSAT1-FLAG-PSAT1, or shPSAT1-PKM2NLS-K433Q).
i.

Base agar: Prepared as described above.

ii.

Top agar: (Each condition, 4 plates) 1.9 ml of warmed 2% noble agar were mixed with 12
ml of warmed 10% FBS media containing 4500 cells. 3 ml of the mixture was then added
to the top of the base agar and incubated at room temperature until solidified. Then, cells
were cultured in humidified incubators at 37 0C and 5% CO2 for 21days.

iii.

Maintenance of culture with feeding media: 2.5 ml of warmed 2% noble agar were mixed
with 27.5 ml of warmed 10% FBS media. Cells were then fed with 1.5 ml of feeding media
every 3-4 days during 21-day incubation. At the end of the study, whole plate images were
captured, and colonies were counted via Image J cell counting tool.

Wound-healing assay with metabolite supplementation
Control and shPSAT1 PC9 cell lines were plated at 106 cells / well in 6 well-plate and grown
in complete media overnight. Culture media was then changed to serum-free media for 24 hours.
A confluent monolayer of cells was wounded with a 200 µl pipette tip in two different areas in each
well. Cells were washed three times with PBS and cultured in 4 ml of low serum-RPMI media (1%
FBS) with or without metabolites (1XNEAA + 1XNucleoside + 500 µM α-KG). Six different images
(4x magnification) were captured from wounded areas at 0- and 24-hour time points and analyzed
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using Image J software with MRI wound healing tool. The migrated area was calculated by
subtraction of wound area (arbitrary unit) at 24 hours from the initial wound area.
Whole-cell protein extracts and subcellular fractionation
Whole-cell lysate protein extraction was performed via Pierce IP lysis buffer supplemented
with PMSF, protease inhibitor, and phosphatase inhibitor according to manufacturer protocol
(Thermo Fischer Sci, 87787).
Cytosolic and nuclear proteins were isolated using the NE-PER kit (Thermo Fischer Sci.,
78835). 15 µg of cytoplasmic protein and 25 µg of nuclear protein were used for immunoblotting
analyses.
Immunoblotting
Proteins within whole-cell lysates, cytosolic and nuclear fractions were separated by SDSPAGE and transferred to PVDF membrane. Blocked membranes were then incubated with the
indicated primary antibodies. Protein detection was performed using the appropriate HRPconjugated secondary antibody and visualized by chemiluminescence (ECL Prime, GE
Healthcare).
Luciferase reporter assay
Control-EV, shPSAT1-EV, and shPSAT1-FLAG-PSAT1 PC9 cells were plated into 6-well
plates and transfected with 2 µg of pGL4.49[luc2P/TCF-LEF/Hygro] using jetPEI with overnight
incubation (media changed after 24 hours). Forty-eight hours post-transfection, stably transfected
cells were selected in 200 µg/ml hygromycin (TCF-LEF vector), 200 µg/ml geneticin (pcDNA3.1
vector), and 1 µg/ml puromycin (shRNA vector). For each study, 4 x 105 stable cells were plated
into each well of a 6-well plate (3 replicates for each condition). Next day, cells were switched to
serum-free media and maintained for 24 hours. Cells were then harvested according to DualLuciferase Reporter Assay protocol. Firefly luciferase activity was determined using 96-well plate
luminometer. Protein concentration of samples was measured by BCA Protein assay and used to
normalize the luciferase activity.
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Phalloidin staining
Cells were plated into 4-well chamber slides and incubated in serum-free media for 24
hours. They were then fixed with 3.7% paraformaldehyde in PBS solution for 10 minutes at room
temperature and washed three times with PBS. Following washes, they were permeabilized with
0.1% Triton X-100 in PBS for 3 minutes and washed again. For visualization, cells were incubated
with a Rhodamine Phalloidin (Invitrogen, R415) working solution (5µl stock/200 µl PBS) for 20
minutes in the dark at room temperature. After additional washing with PBS (3X), slides were
covered with SlowFade Diamond Antifade Mountant with DAPI (S36964) reagent. Images were
captured by Olympus FV-3000 confocal microscope equipped with Fluoview software (Olympus
America Inc) under 40X magnifications.
RNA-seq transcriptomic profiling
Three sets of RNA for RNA-seq profiling were prepared from 24 hour- serum-starved
Control and shPSAT1 PC9 cells. Samples were submitted to the UofL Genomics Facility, which
performed the library preparation and sequencing reactions. Sequencing was performed on the
Illumina NextSeq 500 using the High Output Kit v2 with 75 cycles (cat# FC-40402005) within the
CGeMM facility. Initial data analysis was performed by the KBRIN Bioinformatics core. Normalized
FPKM (Fragments Per Kilobase of transcript per Million mapped reads) expression values and
statistical analysis results, including p- and q-value with ENSEMBL gene ID, were downloaded for
further investigation.
The following parameters served as the selection criterion for differentially expressed
genes, |log2[FC]| ≥0.48, FPKM value (Control or shPSAT1) ≥ 5, and q-value ≤0.05. Genes were
divided into two groups: down-regulated genes (termed shPSAT1-down-regulated) and upregulated genes (termed shPSAT1-up-regulated) as identified in comparisons between shPSAT1
PC9 cells and control cells. As MsigDB v7.2 (Molecular Signatures Database) (https://www.gseamsigdb.org/gsea/msigdb) provides several categories for gene set analysis, KEGG pathway
analysis, CGP (chemically and genetically perturbed data sets), gene ontology (GO) analysis with
GO_BP (biological process) and GO_CC (cellular component), and positional gene set analysis
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tools were utilized in this project based on TOP 20 list for KEGG pathway analysis and TOP 50 for
others with FDR ≤0.05 (167). Potential transcription factors involved in the alteration of gene
expression were identified by the transcription factor analysis tool of WebGestalt 2013 (WEB-based
GEne SeT AnaLysis Toolkit) (http://www.webgestalt.org/2013/) using the hypergeometric test with
adj-p≤0.001 with at least 10 gene targets (168).
Public microarray datasets analysis
i.

Data search and import
The EGFR mutant lung cancer datasets were chosen based on the number of EGFR

mutant tumor samples (n>10) with paired or unpaired normal tissue samples and the availability of
relevant clinical information. According to these selection criteria, GSE31210, GSE27262,
GSE31547, GSE31548, GSE32863, and GSE75037 datasets were imported to BRB-ArrayTool
using its NCBI GEO Series tool (151).
ii.

Identification of common gene sets and survival analysis
shPSAT1-mediated down-regulated and up-regulated gene lists obtained from the RNA-

seq analysis were prepared separately as text files and saved under the user gene list folder under
the program files of ArrayTool. Expression of these genes was filtered using the ArrayTool- re-filter
option and normalized. Data was utilized with the exclusion of those genes whose expression was
less than 20% of expression data and less than 1.5- fold change in either direction from the gene’s
median value options. Differentially expressed genes from our RNA-seq profiling were directly
compared to those gene changes between EGFR mutant tumor and normal lung samples using
the ArrayTool-Class Comparison plugin and the significance threshold of univariate analysis with
p≤0.05 served as statistical analysis criteria. This was done to identify PSAT1 regulated genes that
are also differentially expressed in EGFR-mutant NSCLC. Importantly, up-regulated genes in
EGFR tumors would be down-regulated by shPSAT1 and vice-versa. Genes with fold-changes
(EGFR mutant tumor/ Normal lung) ≥ 1.4 found in our shPSAT1-down-regulated genes list and
genes with fold-changes (EGFR mutant tumor/ Normal lung) ≤ 0.71 found in our shPSAT1-up-
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regulated genes list were assigned as PSAT1-associated genes linked with EGFR mutant lung
cancer. This procedure was repeated for each dataset: GSE31210, GSE27262, GSE31547,
GSE31548, GSE32863, and GSE75037.
The common gene sets were determined via Venn diagram comparisons using
http://bioinformatics.psb.ugent.be/webtools/Venn/. The expression of common genes from each
dataset was extracted using the ArrayTool-Class Comparison tool. Cluster analysis and heatmap
generation were performed with dChiP software using the following criteria: Euclidean distance with
average linkage analysis (171).
Among the datasets, GSE31210 was the only set encompassing all of the following clinical
information on defined NSCLC genotypes: KRAS mutant and EGFR/KRAS wild-type tumor data
in addition to EGFR mutant lung tumors and their pathological stage, relapse and survival events,
and duration data. Therefore, survival predictions using the expression data of the PSAT1associated common gene lists were performed by the BRB-ArrayTool survival risk prediction
function (170). Principal component analysis with leave-one-out cross-validation and log-rank
statistics with 100 permutation tests were used for analysis and p≤0.05 was considered statistically
significant. This analysis calculated the prognostic indexes and classified the patients based on
this index as high risk and low risk groups.
iii.

Identification of a potential PSAT1-associated metastatic gene signature
GSE14107 was imported as described above due to the presence of a genome-wide

expression profile of both parental PC9 cells and its metastatic brain subline of PC9-BrM3 (172).
Differentially expressed genes were determined by ArrayTool- Class comparison plugin using the
significance threshold of univariate analysis with p≤0.05. Down-regulated and up-regulated gene
lists were assigned based on fold-change (PC9-BrM3/PC9-Parental) 0.71 ≥ and 1.4 ≤, respectively.
The GSE14107 gene list was compared with the differential expression gene list from our PC9shPSAT1 RNA sequencing analysis by http://bioinformatics.psb.ugent.be/webtools/Venn/ to find
common genes. Cluster analysis and heatmap generation of common gene expression derived
from the GSE14107 dataset were performed by dChiP software.
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Statistical analysis
All data were statistically analyzed using Prism 8 software (GraphPad Software). Statistical
significances were assessed based on the number of groups with one or more independent
variables. Repeated Measure one-way ANOVA with Tukey's multiple comparison test for three
groups was performed for both PSAT1 and nuclear PKM2 rescue study. Two-way ANOVA with
Tukey's multiple comparison test was used for wound-healing assay with metabolite
supplementation. The statistical significance for soft agar assay with metabolite supplementation
was determined by two-step analysis: firstly, two-way ANOVA with Dunnet’s multiple comparison
test was performed with raw data to examine the effect of metabolite supplementation on both
control and shPSAT1 cells. Then, the ratio of colony number (shPSAT1/Control) within each
treatment was used for repeated measure one-way ANOVA with Dunnet’s multiple comparison test
to assess the rescue effect.

Experimental replicates for each analysis are stated within the

respective figure legend. Values of p ≤ 0.05 were considered statistically significant.

84

Results
Determination of differentially expressed genes (DEG) in PSAT1 silenced PC9 cells
In the previous chapter, we used biochemical approaches to examine the role of PSAT1 in
NSCLC tumorigenesis. We found that PSAT1 interacts with PKM2 and contributes to PKM2’s
nuclear localization in EGFR-activated NSCLC cells. Unexpectedly, we also observed PSAT1
within the nuclear compartment of the EGFR-activated cells. Thus, we conducted a genome-wide
gene expression profiling study using RNA-seq technology to potentially uncover unknown cellular
processes that are impacted by PSAT1 loss.
Three separate sets of RNA were extracted from distinctly grown control and shPSAT1
PC9 cells and submitted for sequencing and statistical analysis to the genomics core facility within
the James Graham Brown Cancer Center in partnership with the Kentucky Biomedical Research
Infrastructure Network (KBRIN). Their initial analysis provided normalized expression values of
genes in FPKM (fragments per kilobase of transcript of million mapped reads) with annotation
tables, log2(FC) (log2(foldchange)), p-values, and q-values (adjusted p-value). From this, we
determined the differentially expressed genes (DEG) based on the following criteria: FPKM≥ 5,
fold-change ≥ 1.4 (|log2(FC)|≥ 0.48), and q-value ≤ 0.05. Heatmaps of both down-regulated and
up-regulated genes resulting from PSAT1 silencing were created by dChiP software and presented
in Figures 28 & 29, respectively (171). In sum, we found 279 down-regulated and 211 up-regulated
genes for further analysis.
Pathways and biological processes affected by PSAT1 suppression
Molecular signature database (MSigDB) is a user-friendly database created and
maintained by the Broad Institute (https://www.gsea-msigdb.org/gsea/msigdb/index.jsp) (167).
MSigDB stores more than thirty thousand annotated gene sets under 9 different subjects for gene
set analysis including, hallmarks of gene sets, positional gene sets, curated gene sets, regulatory
target gene sets, computational gene sets, ontology gene sets, oncogenic signature gene sets,
immunologic gene sets, and cell type signature gene sets. These major subjects have been further
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Figure 28. Heatmap demonstrating down-regulated genes upon PSAT1 silencing.
Color key (Blue, Red)→ (-2,2).

86

Figure 29. Heatmap demonstrating up-regulated genes upon PSAT1 silencing.
Color key (Blue, Red)→ (-2,2).
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divided into sub-groups. For example, curated gene sets consist of gene sets for pathway analysis,
including KEGG, BIOCARTA, PID, and REACTOME. Users are able to upload individual gene sets
for comparison to the curated sets within MSigDB. The overlapping genes are then identified along
with statistical analysis values: p and FDR, which can be downloaded in a text format.
Down-regulated and up-regulated gene lists obtained from our RNA-seq studies were
uploaded separately to MSigDB for KEGG pathway analysis based on Top 20 pathways with
FDR≤0.05. Results were plotted as number genes in the indicated pathways and presented in
Figure 30. The affected pathways identified with the down-regulated gene set included cell cycle,
pathways in cancer, and MAPK signaling pathway (Fig. 30A). These are commonly dysregulated
pathways involved in tumorigenesis and confirm the oncogenic effect of PSAT1 at the
transcriptional level. Down-regulated genes within folate biosynthesis, glutathione metabolism, and
purine and pyrimidine metabolism linked dysregulation of serine biosynthetic pathway with loss of
PSAT1 metabolic function. Paradoxically, KEGG pathway analysis of up-regulated genes also
found cancer-related pathways involving MAPK signaling pathway, ERBB signaling pathway,
pathways in cancer, and endometrial cancer (Fig. 30B). However, we found that 20.7 % of downregulated genes were attributed to cancer-related pathways, while only 11.84 % of up-regulated
genes were included in this pathway analysis.
Next, we performed gene ontology (GO) analysis using MSigDB- GO_BP (Biological
Process) and GO_CC (Cellular Component) tools to gain deeper insight into PSAT1-associated
gene signatures. Top 50 signatures with FDR ≤0.05 served as our selection criteria. GO
terminologies were grouped under general biological process titles in order to highlight the overall
cellular changes upon PSAT1 silencing. GO_BP and GO_CC analysis of down-regulated genes
were summarized in Tables 3 and 4. Similarly, GO_BP and GO_CC of upregulated genes were
presented in Tables 5 and 6.
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A

B

Figure 30. KEGG pathway analysis of differentially expressed genes. A) shPSAT1down-regulated genes and B) shPSAT1-up-regulated genes. FDR≤0.05.
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Table 3. GO_BP analysis of shPSAT1-down-regulated genes

Table 4. GO_CC analysis of shPSAT1-down-regulated genes

GO_NUCLEAR_BODY
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GO_CHROMATIN

Membrane

GO_SUPRAMOLECULAR_COMPLEX

Table 5. GO_BP analysis of shPSAT1-up-regulated genes
Biological
Function

GO_BP terms
GO_CELL_MOTILITY
GO_LEUKOCYTE_MIGRATION

Motility

GO_CELL_CHEMOTAXIS
GO_CELL_PROJECTION_ORGANIZATION
GO_MYELOID_LEUKOCYTE_MIGRATION
GO_CELL_ACTIVATION
GO_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE
GO_BIOLOGICAL_ADHESION

Immune
Response

GO_INFLAMMATORY_RESPONSE
GO_MYELOID_LEUKOCYTE_MEDIATED_IMMUNITY
GO_IMMUNE_EFFECTOR_PROCESS
GO_LEUKOCYTE_CHEMOTAXIS
GO_DEFENSE_RESPONSE

Genes

EGFR, APP, RAC1, S100A9, HDAC9, PDGFA, ALOX5, TNFRSF11A, GLUL, CSF1R,
SMAD3, EFNB2, FOLR1, CCL20, CXCL1, B4GALT1, SDC4, ADGRE2, STC1, GBF1,
CLDN1, JAG1, TRIB1, ATP2B4, EPS8, HBEGF, TNS3, RIN2, ITGB8, SPOCK1,
MEGF9, PLA2G7, DEFB1, SRGAP1, ARID5B, LRP12, TNC, AREG, ROR1, LCN2,
BTG2, SPTBN1, KIDINS220, KLK6, FSTL4, MYLIP, DDX56, FGD4, NUDCD3

EGFR, APP, RAC1, S100A9, HDAC9, PDGFA, ALOX5, TNFRSF11A, CSF1R,
SMAD3, EFNB2, FOLR1, CCL20, CXCL1, B4GALT1, SDC4, ADGRE2, STC1, GBF1,
CLDN1, JAG1, HBEGF, RIN2, ITGB8, SPOCK1, MEGF9, PLA2G7, DEFB1, LRP12,
C3, TLR1, ABCA1, IGFBP2, TNC, AREG, GJB2, CACNG4, CALCOCO1, PCDH1,
GPRC5B, AOC1, LCN2, FTH1, CDK13, CD22, CFD, QPCT, TCN1, TMEM179B,
AGR2, AHR, VTCN1, LFNG, TXNIP, CTSV, FBXO32, NEAT1, CREBRF, PMEPA1,
DSC2, TJP2, PI3, RAMP1, LYPD3, SPTBN1, SNX18, HLA-DQB1, CFB, TPCN2,
BPIFB1, GBP2, TMPRSS4, ATP9A

GO_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND
GO_RESPONSE_TO_ORGANIC_CYCLIC_COMPOUND
GO_RESPONSE_TO_LIPID
Response to
Exogenous
signals

GO_RESPONSE_TO_ENDOGENOUS_STIMULUS
GO_RESPONSE_TO_CORTICOSTEROID

EGFR, APP, RAC1, S100A9, HDAC9, TNFRSF11A, GLUL, CSF1R, SMAD3, FOLR1,
CCL20, CXCL1, STC1, GBF1, CLDN1, JAG1, TRIB1, ATP2B4, EPS8, DEFB1, C3, TLR1,
ABCA1, ANO1, IGFBP2, TNC, AREG, GJB2, CACNG4, EIF4EBP2, CALCOCO1, LATS2,
AOC1, LCN2, CFD, AHR, VTCN1, TXNIP, BTG2, CTSV, FBXO32, DGAT2, CREBRF,
PMEPA1, EPG5, PI3, RAMP1, KIDINS220, HLA-DQB1, CFB, BPIFB1, GBP2, LSM5
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GO_RESPONSE_TO_STEROID_HORMONE
GO_RESPONSE_TO_BIOTIC_STIMULUS

Cell Signaling

GO_CELL_CELL_SIGNALING
GO_RESPONSE_TO_ENDOGENOUS_STIMULUS
GO_POSITIVE_REGULATION_OF_SIGNALING
GO_ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY
GO_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION
GO_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY
GO_EPIDERMAL_GROWTH_FACTOR_RECEPTOR_SIGNALING_PATHWAY
GO_SECRETION
GO_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION
GO_EXOCYTOSIS
GO_REGULATION_OF_TRANSPORT
GO_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT

Molecular
Function

GO_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY
GO_REGULATION_OF_PROTEIN_KINASE_ACTIVITY
GO_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS
GO_REGULATION_OF_TRANSFERASE_ACTIVITY
GO_LIPID_METABOLIC_PROCESS
GO_ENDOCYTOSIS
GO_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS
GO_EPITHELIUM_DEVELOPMENT

Development

GO_TUBE_MORPHOGENESIS
GO_NEUROGENESIS

Proliferation

GO_REGULATION_OF_CELL_POPULATION_PROLIFERATION

EGFR, APP, RAC1, S100A9, HDAC9, PDGFA, ALOX5, TNFRSF11A, GLUL, CSF1R,
SMAD3, EFNB2, FOLR1, CCL20, STC1, GBF1, CLDN1, JAG1, TRIB1, ATP2B4, EPS8,
HBEGF, SRGAP1, ARID5B, C3, TLR1, ABCA1, ANO1, PER2, IGFBP2, TNC, AREG,
GJB2, CACNG4, EIF4EBP2, CALCOCO1, ROR1, SCEL, PCDH1, GPRC5B, LATS2,
SYNPO, TCF7L1, GABBR2, AOC1, CD22, AGR2, AHR, LFNG, TXNIP, BTG2, CTSV,
FBXO32, CREBRF, PMEPA1, RAMP1, SPTBN1, KIDINS220, MAP3K1, GPRC5A,
ARHGAP23, KLK6, FSTL4, BMF, SOS2, FGD4, FAM83A, DEPTOR, PIK3IP1

EGFR, APP, RAC1, S100A9, HDAC9, PDGFA, ALOX5, TNFRSF11A, GLUL, CSF1R,
SMAD3, EFNB2, FOLR1, CCL20, CXCL1, B4GALT1, SDC4, ADGRE2, STC1,
CLDN1, JAG1, TRIB1, ATP2B4, HBEGF, RIN2, ITGB8, PLA2G7, DEFB1, SRGAP1,
ARID5B, LRP12, C3, TLR1, ABCA1, ANO1, PER2, AREG, CACNG4, ROR1,
GPRC5B, LATS2, AOC1, LCN2, FTH1, CDK13, CD22, CFD, QPCT, TCN1,
TMEM179B, AGR2, TNFAIP2, LFNG, DGAT2, SGPP2, PMEPA1, DSC2, LIPK,
RAMP1, KIDINS220, MAP3K1, GPRC5A, ARHGAP23, SNX18, SNX13, DCP1B, H1-0,
MYLIP, CREBL2, TPCN2, TOMM7, ICE1, EEPD1, SLC43A2, TSPAN13, DEPTOR,
CCNL2, KPNA7, STX5, PIK3IP1, MTMR1, RBP1, AKR1B15, CYP4V2, ALDH3B2,
THNSL2, STARD3NL, TMPRSS4, ATP9A, WDR70

EGFR, APP, RAC1, S100A9, HDAC9, PDGFA, ALOX5, GLUL, CSF1R, SMAD3,
EFNB2, FOLR1, B4GALT1, SDC4, STC1, CLDN1, JAG1, ATP2B4, HBEGF, TNS3,
RIN2, ITGB8, SPOCK1, LRP12, C3, PER2, TNC, AREG, GJB2, ROR1, SCEL,
GPRC5B, AGR2, TNFAIP2, LFNG, TXNIP, BTG2, CTSV, DSC2, TJP2, PI3, LIPK,
KRT6B, RAMP1, SPTBN1, KIDINS220, KLK6, FSTL4, MYLIP, DDX56
EGFR, APP, PDGFA, ALOX5, TNFRSF11A, GLUL, CSF1R, SMAD3, EFNB2, CXCL1,
B4GALT1, SDC4, CLDN1, JAG1, TRIB1, HBEGF, TNS3, PER2, IGFBP2, TNC,
AREG, FTH1, CDK13, CD22, AHR, VTCN1, TXNIP, BTG2, NEAT1, SGPP2, H2AC6

Table 6. GO_CC analysis of shPSAT1-up-regulated genes
GO_CC terms

Genes

GO_INTRINSIC_COMPONENT_OF_PLASMA_MEMBRANE

APP, EGFR, SDC4, FOLR1, ABCA1, TLR1, CACNG4,
ITGB8, RAMP1, ROR1, CSF1R, HBEGF, CD22,
GABBR2, EPS8, GPRC5A, ANO1, ATP2B4, CLDN1,
JAG1, EFNB2, GJB2, PCDH1, SLC28A3, ADGRE2,
LRP12, RCE1, LYPD3, EEPD1, OPN3, TSPAN13,
CD82, TM4SF1, PDGFA, B4GALT1, RAC1, C3, CTSV,
TMEM179B, BMF, AREG, STX5, HLA-DQB1, PMEPA1,
SLC29A3, ATP9A, GPRC5B, VTCN1, TNFRSF11A,
SMAD3, AHR, SNX18, STARD3NL, TPCN2, SNX13,
PEX6, TOMM7, SLC4A11, IGFBP2, STC1, SPTBN1

GO_CELL_SURFACE
GO_RECEPTOR_COMPLEX
Cell Membrane

GO_WHOLE_MEMBRANE
GO_PLASMA_MEMBRANE_REGION
GO_APICAL_PART_OF_CELL
GO_APICAL_PLASMA_MEMBRANE
GO_G_PROTEIN_COUPLED_RECEPTOR_COMPLEX
GO_ANCHORING_JUNCTION

Junction/Projection

GO_ACTIN_BASED_CELL_PROJECTION
GO_GLIAL_CELL_PROJECTION
GO_GOLGI_APPARATUS
GO_SECRETORY_VESICLE
GO_VESICLE_LUMEN
GO_GOLGI_MEMBRANE

Golgi/Secretion

GO_VESICLE_MEMBRANE
GO_ENDOPLASMIC_RETICULUM_GOLGI_INTERMEDIATE_COMPARTMENT
GO_ENDOSOME
GO_FICOLIN_1_RICH_GRANULE

APP, EGFR, SDC4, ITGB8, EPS8, CLDN1, JAG1,
EFNB2, GJB2, PCDH1, PDGFA, B4GALT1, RAC1,
CTSV, AOC1, FGD4, DSC2, SYNPO, TJP2, TNC,
TNS3, GLUL
APP, EGFR, SDC4, FOLR1, ABCA1, TLR1,
CACNG4, HBEGF, CD22, GPRC5A, GJB2, PDGFA,
B4GALT1, RAC1, CDK13, C3, CTSV, AOC1, QPCT,
CXCL1, TCN1, LCN2, ALOX5, CFD, S100A9,
TMEM179B, BMF, FTH1, KLK6, FSTL4, TMPRSS4,
AREG, STX5, HLA-DQB1, PMEPA1, SLC29A3,
ATP9A, GBF1, MAN1A1, GBP2, LFNG, CHST12,
HS6ST2, FGD4, DEFB1, RETREG1, H1-0,
SLC39A11, CAPN8, GPRC5B, SNX18, STARD3NL,
TPCN2, SNX13, SLC4A11, KIDINS220

GO_VACUOLE
GO_SPECIFIC_GRANULE
GO_NUCLEAR_ENVELOPE_LUMEN
Others

GO_LIPID_DROPLET
GO_PERINUCLEAR_REGION_OF_CYTOPLASM
GO_CORNIFIED_ENVELOPE

APP, EGFR, ABCA1, GJB2, ALOX5, ATP9A, GBF1,
GBP2, DSC2, EPG5, DGAT2,
ALDH3B2, RBP1, SCEL, PER2, PI3
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Cellular Localization

The serine synthetic pathway provides precursors for anabolic pathways such as
nucleotide and lipid biosynthesis to promote tumor growth (Fig. 31A)(16, 28). As mentioned above,
KEGG pathway analysis confirmed the decreased SSP activity upon PSAT1 silencing. Accordingly,
GO analysis with down-regulated genes implicated genes involved in maintaining chromatin
structure, participating in DNA metabolism, and influencing cell proliferation (Tables 3 & 4). As a
result, we speculated that the metabolic activity of PSAT1 contributes to the oncogenic capacity of
EGFR-mutant NSCLC cells.

For this, we performed soft agar assays with or without

supplementation of SSP-downstream metabolites, including non-essential amino acids (NEAA),
nucleosides, and α-ketoglutarate (α-KG). We observed that depletion of PSAT1 resulted in a 40%
reduction in colony formation in comparison with control cells (Fig. 31B). The addition of downstream metabolites alone did not affect the ratio of colony number (shPSAT1/Control). However,
the combination of any metabolite(s) with nucleosides significantly increased the ratio of colony
number in comparison with media without supplementation. To further understand the putative
metabolic role, soft agar assays were repeated with the genetic rescue of PSAT1 or expression of
nuclear acetyl-mimetic PKM2 in PC9 cells, as was done in Chapter 2. Restoration of PSAT1 (Fig.
31D), but not PKM2NLS-K433Q (Fig. 31C), recapitulated the phenotype of control cells. Taken
together, these results are consistent with the RNA sequencing analysis and implicate the
metabolic function of PSAT1 contributes to anchorage-independent growth.
Next, we investigated the contribution of PSAT1-downstream metabolites on cell migration.
A wound-healing assay was performed in the presence or absence of all metabolites (NEAA+
nucleoside + α-KG). Unlike the soft agar assays, we found that the addition of metabolites did not
rescue the loss of PSAT1 mediated migration deficiency (Fig. 32). This supports our previous
findings that a putative novel non-canonical function of PSAT1, including facilitation of nuclear
PKM2 localization, contributes to cell migration.
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A

B

C

D

Figure 31. The metabolic activity of PSAT1 contributes to anchorage-independent
growth. A) Serine synthetic pathway. (B-D) Soft agar assays analysis for B) metabolite
supplementation, C) nuclear PKM2 restoration, and D) PSAT1 restoration. N=3, *,
p≤0.05 and **, p≤0.01. EV: empty vector and NS: Not significant.
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B

Figure 32. The addition of downstream metabolites fails to induce cell migration
in PSAT1 silenced cells. A) Representative images of wound-healing assay. B)
Quantification of migration. N=3, *, p≤0.0001, NS: not significant, and A.U,: arbitrary
unit.
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Validation of PSAT1 mediated gene changes in EGFR-mutant NSCLC cells
Our KEGG pathway analysis described above found significantly altered cell cycle process
in the absence of PSAT1 (Fig. 30). To explore genes involved in the RB/E2F pathway’s functional
role in regulating the cell cycle, we utilized the DEG list from our RNA-seq studies and performed
gene set analysis using the MSigDB CGP (chemical and genetic perturbations) tool that harbors
curated gene lists from other genome-wide gene expression studies and transcription factor
analysis by WebGestalt 2013 (167, 168). The results for the gene set analysis were presented in
Figure 33A. We found a high number of downregulated genes that significantly overlapped with
genes within “FISCHER_ G1/S_CELL _CYCLE” (30 genes, p= 2.6e-31, FDR= 7.82 e-28) and
“CHICAS_RB1_TARGETS_SENESCENT” (37 genes, p= 2.85e-25, FDR= 1.37e-22) that function
in RB/E2F pathway. Furthermore, nineteen of the down-regulated genes possessed E2F binding
sites within their promoter regions. Expression values of E2F family members and RB1 were
extracted from our RNA-seq data and plotted to determine any changes at the transcriptional level.
As shown in Figure 33B, E2F1 and E2F8 were significantly downregulated in PSAT1 silenced cells.
Taken together, our analysis corroborates previous reports that PSAT1 contributes, in part, to cell
cycle progression through modulating the RB/E2F pathway (1).
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B

Figure 33. Gene set analysis confirms the link between PSAT1 and RB/E2F mediated
cell cycle progression. A) Summary of gene set and transcription factor analyses. B) Log
transformed FPKM value of E2F family and RB expression. *, q≤0.05; q: Adjusted p-value
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PSAT1 may mediate β-catenin transactivation through regulating protein expression
EGFR activation promotes the nuclear localization of β-catenin through various
mechanisms. While phosphorylation of membranous β-catenin by EGFR or AKT leads to migration
of β-catenin away from the membrane, EGFR activation inhibits the proteasomal degradation of
cytoplasmic β-catenin protein by GSK3β inactivation. Thus, both EGFR-mediated pathways result
in the accumulation of β-catenin in the nucleus (63, 173-175). Nuclear β-catenin is associated with
poor overall survival in patients with EGFR mutant lung cancer (174). Although a role for nuclear
β-catenin in tumor initiation and cell migration has been shown in EGFR mutant lung cancer models
(176, 177), the contribution of nuclear β-catenin activity to the development of EGFR-TKI resistance
is of significant interest since EGFR-TKI resistant NSCLC cells developed various mechanisms to
promote β-catenin stabilization and activation (176-183). In short, nuclear β-catenin seems to
contribute to every step within EGFR-driven tumor progression.
β-catenin is another downstream target of the GSK3β pathway that has previously been
examined (43, 79). Reduction in β-catenin level has been observed together with phospho-GSK3β
upon PSAT1 silencing, impacting cell cycle and proliferation in ER-negative breast cancer cells and
resistance in ovarian cancer cells while inducing apoptosis. However, the connection between βcatenin and PSAT1 remains elusive in EGFR mutant NSCLC cells. Furthermore, nuclear PKM2
requires EGF-induced β-catenin transactivation in EGFR-driven tumor growth of GBM and EGFinduced EMT and invasion in HCC cells (100, 113). Considering these previous reports and our
results showing the link between PSAT1 and nuclear PKM2, we speculated that loss of PSAT1
may result in altered β-catenin transactivation.
First, we performed gene set analysis with our PSAT1-mediated DEG list utilizing the
MSigDB-CGP tool and transcription factor analysis by WebGestalt 2013. As β-catenin induces
transcription via interacting with TCF/LEF1 transcription factor family, genes with LEF1 binding
sites were assumed as potential β-catenin targets (162, 164). The summary of our gene
comparison analysis was shown in Figure 34A. While overlapping shPSAT1-down-regulated genes
within the “FEVR_CTNNB1_TARGETS_DN” gene set suggested a reduction in β-catenin
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transactivation in PSAT1 silenced cells, paradoxically, we also found down-regulated genes within
the “WANG_RESPONSE_TO_GSK3B_INHBITOR_SB216763_DN” gene set, which indicated a
possible activation of β-catenin upon PSAT1 loss. Furthermore, transcription factor analysis found
LEF1 promoter binding sites in genes from both down and up-regulated gene lists. In short, these
analyses did not provide any clear insight into whether β-catenin transactivation may change upon
PSAT1 silencing. Thus, we extracted the expression data of β-catenin (CTNNB1) and TCF(T-cell
specific transcription factor) family (TCF7(TCF-1), LEF1, TCF7L2 (TCF-4), TCF7L1(TCF-3)) and
compared their transcript levels between control and stable PSAT1 shRNA expressing PC9 cells
(162, 173). We did not observe any significant change in the mRNA expression level of β-catenin
and TCF/LEF1 transcription factor except TCF7L1 with a 1.47-fold increase in PSAT1 silenced
cells (Fig. 34B). As TCF7L1 is a known repressor, this may reduce the β-catenin-TCF/LEF1 target
gene expression (173). Overall, our gene set analysis was unable to provide any definitive link
between PSAT1 and β-catenin transactivation in our PC9 cell model.
To better understand the connection between PSAT1 and β-catenin, we next assessed
whether β-catenin protein expression was altered in the presence or absence of PSAT1. In Figure
35A, immunoblot analysis found that β-catenin expression decreased upon PSAT1 silencing, which
can be rescued by re-expression of PSAT1. We then examined whether nuclear PKM2 expression
(as assessed by PKM2NLS-K433Q) would affect β-catenin expression under PSAT1 silencing. We
found no rescue of β-catenin expression with nuclear acetyl-mimetic PKM2, indicating that
regulation of β-catenin expression is independent from nuclear PKM2 level in the context of PSAT1
loss (Fig. 35B).
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B

Figure 34. PSAT1 mediated DEG are compared with genes within the GSK3β/βcatenin related pathway. A) Summary of gene set and transcription factor analyses. B)
Log transformed FPKM value of TCF/LEF1 family and CTNNB1 expression. *, q≤0.05; q:
Adjusted p-value.
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Figure 35. Suppression of PSAT1 reduces β-catenin protein levels. (A-B) Immunoblot
analysis of β-catenin expression and quantification in A) PSAT1 rescued shPSAT1 PC9
cells (N=3) and B) Nuclear PKM2 rescued shPSAT1 PC9 cells (N=5). White arrow: nonspecific band. *, p≤0.05; **, p≤0.01, and NS: not significant.
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Accumulation of cytoplasmic β-catenin due to inhibited proteasomal degradation leads to
its nuclear localization and transactivation (83, 175). Since we found a reduction in total β-catenin
levels, we next examined its cellular distribution upon PSAT1 silencing. Thus, subcellular
fractionation was performed, and the cytoplasmic and nuclear distribution of β-catenin was
assessed by immunoblotting. We found that nuclear β-catenin decreased in PSAT1 silenced cells
in comparison with control cells, which could be rescued upon re-expression of PSAT1 (Fig. 36A).
Yet, we also observed the same pattern of β-catenin expression in the cytoplasmic fraction (SE;
short exposure). These results, together with our findings from whole-cell lysates (Fig. 35A) and
mRNA expression profiles (Fig. 34B), imply that PSAT1 contributes to β-catenin stability in PC9
cells, possibly through increasing phospho-GSK3β level.
We then aimed to directly measure β-catenin transcriptional activity with an established
luciferase reporter assay system. To achieve this goal, cells were stably transfected with the
luc2p/TCF-LEF vector. Cells were maintained in serum-free media for 24 hours in order to directly
assess mutant activated EGFR-dependent β-catenin transactivation. Figure 36B demonstrates that
loss of PSAT1 significantly decreased luciferase activity compared to control cells, while PSAT1
re-expression completely rescued β-catenin transcriptional activity. Taken together, our findings
suggest that PSAT1 affects β-catenin transactivation through regulating its stability.
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B

Figure 36. Suppression of PSAT1 reduces β-catenin transactivation. A) Immunoblot
analysis of cytoplasmic and nuclear β-catenin expression (N=3). B) TCF-Luciferase
reporter assay for the assessment of β-catenin-TCF transactivation (N=4). *, p≤0.05.
White arrow: non-specific band. EV: Empty vector and SE: short exposure
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Silencing of PSAT1 impacts the actin cytoskeleton organization via decreasing the
expression of actin regulating genes
The actin cytoskeleton not only determines cellular morphology but plays key roles in
tumorigenic processes such as migration and invasion due to the requirement for cell movement
(184). As our previous results found a requirement for PSAT1 in cell migration, we speculated that
loss of PSAT1 may impact the organization of the actin cytoskeleton. To assess this, we used
immunofluorescence microscopy with phalloidin staining that is commonly used to visualize actin
stress fibers through binding to F-actin (filamentous actin) (185). As shown in Figure 37, confocal
microscopy found that control PC9 cells exhibited structured actin fibers spanning the whole cell
body, while cells devoid of PSAT1 displayed loss of these actin stress fibers. Yet, re-expression of
PSAT1 in silenced cells rescued the long fiber formations, thereby validating PSAT1’s on-target
effects and confirming a role for PSAT1 in actin cytoskeleton organization.
Next, we further scrutinized our PSAT1-mediated DEG lists to identify genes involved in
actin-related processes. Firstly, we extracted gene lists from the MSigDB database stratified under
the GO_Actin_ [Binding, Cytoskeleton, Filament Organization] categories and determined
overlapping genes with our DEG list. We found 15 genes related to actin cytoskeleton regulation
within our shPSAT1-down-regulated gene list (Fig. 38).
Formin Homology 2 Domain Containing 1 (FHOD1) functions as an actin filament capping
and bundling protein, unlike other formin members with nucleation and elongation activity (186). It
is activated via phosphorylation by the RhoA-ROCK pathway and subsequently promotes stress
fiber formation. While depletion of FHOD1 in cells leads to decreased stress fiber formation, thicker
actin fibers have been observed in overexpressed cells (187). The gain and loss of function studies
have shown differential effects of FHOD1 on cell shape through regulating F-actin bundling (188190). Co-localization of FHOD1 with F-actin at the cell periphery suggests that FHOD1 enhances
cell migration via inducing the formation and stabilization of F-actin at the leading edge. Its role in
cancer metastasis is further supported by the observation of elevated expression at the invasive
front of squamous cell carcinoma (SCC) (190).
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#1

#2

Figure 37. Loss of PSAT1 impacts the actin cytoskeleton. Representative images from
two different experiments. Phalloidin staining for F-actin visualization: Real (red) and pseudocolored (gray) images. DAPI served (blue) served as nuclear staining.
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Figure 38. shPSAT1-down-regulated genes involved in actin-related biological
functions.
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TMSB4X encodes a small peptide that is known as thymosin β4 (Tβ4). Its expression has
been linked to aggressive tumorigenic phenotypes such as increased angiogenesis, cell migration,
and metastasis (191). Thymosin β4 is recognized as a G-actin sequestering factor that inhibits
spontaneous actin polymerization (192). It contributes to cell motility via localizing the monomeric
G-actin at the leading edge of lamellipodia for actin polymerization, leading to the formation of
membrane protrusions (193). Thymosin β4 has also been reported as a prognostic factor for poor
survival and metastasis in patients with early-stage NSCLC (194). Furthermore, decreased cell
proliferation, cell migration, and invasion both in vitro and in vivo have been observed in thymosin
β4 silenced A549 and H1299 NSCLC cells (195).
S100A4 is a calcium-binding protein belonging to the S100 family and recognized as a
metastasis-associated protein (196). The prognostic value of S100A4 has been shown in a variety
of cancers, including lung cancer. S100A4 functions as a metastasis-inducing factor in tumor cells
without apparent tumorigenic function. Association with actin-related factors such actin, myosin,
and tropomyosin has been reported, but the mechanism in which S100A4 increases the
lamellipodia stabilization and actin cytoskeleton re-arrangement to promote cell migration remains
elusive (184, 197).
As mentioned above, the common points of FHOD1, TMSB4X, and S100A all share an
interaction with actin, contribute to F-actin formation, and play critical roles in cellular motility. As
PSAT1 loss results in motility defects and changes in actin polymerization, we confirmed the
differential expression of these genes via Real-Time PCR in our NSCLC model.

As shown in

Figure 39, silencing of PSAT1 reduced the expression of each gene, which was fully restored by
re-expression of PSAT1. These results validate our findings from the RNA-seq transcriptomic and
implicate a new role for PSAT1 in cell migration through regulating the expression of actin-related
factors.
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Figure 39. Suppression of PSAT1 reduces the expression of genes involved in Factin formation. Real-time PCR analysis of gene expression. N= 3-4; *, p≤0.05 and **,
p≤0.01
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PSAT1 impacts the expression of genes localized in chr18p11
Serine metabolism can potentially contribute to epigenetic regulation due to the
involvement of one-carbon metabolism or production of -KG (38, 136). Kottakis et al. has found
an epigenetic mechanism for PSAT1 upon the depletion of the tumor suppressor, Lkb1, in a Krasactivated pancreatic cancer transgenic mouse model (46). Increased PSAT1 expression leads to
hypermethylation of DNA, which is mainly enriched in retrotransposons. These hypermethylated
retrotransposons can promote tumor formation through impacting the host gene expression. In
another study, Hwang et al. has demonstrated that PSAT1 participates in the maintenance of stem
cell properties of mouse ESCs via providing the α-ketoglutarate cofactor for α-KG-dependent
dioxygenases that results in hypomethylation of histone and DNA (136). These reports highlight
PSAT1’s potential role in epigenetic regulation.
As epigenetic regulation generally affects transcriptional expression over a broad
chromosomal area, we sought to identify differentially expressed genes located in the same
chromosomal region. Results from this analysis using the MSigDB-positional gene set tool were
presented in Figure 40. Several shPSAT1-down-regulated genes were localized to the chr18p11
cytogenic band, while the chr7p21 cytogenic band harbored various shPSAT1-up-regulated genes.
A genome-wide association study within a Korean population conducted by Ahn et al. found
an association of chr18p11 with never-smoker lung cancer susceptibility (198). Consistent with the
fact that EGFR activation mutation is more common in the never-smoker Asian population, we
chose to examine these genes localized in chr18p11 in response to differential PSAT1 expression
(96). First, we utilized the UCSC genome browser (http://genome.ucsc.edu/) to determine the
genomic position of the genes on chr18p11 cytogenic bands. As shown in Figure 41A, our identified
down-regulated genes were not restricted to a small region but observed spanning the wide-ranging
area within chr18p11. We then picked 8 genes to validate their differential regulation observed in
our RNA-seq studies upon PSAT1 silencing (Fig. 41A, red color). Real-time PCR analysis
confirmed that genes within Chr18p11 were down-regulated upon PSAT1 silencing and partially
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restored by re-expression of PSAT1, with the exception of TYMS (Fig. 41B). This result suggests
potential PSAT1-mediated epigenetic regulation in this region.
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B

Figure 40. Differentially expressed genes are observed in the same cytogenetic bands.
A) sh-PSAT1-down-regulated genes and B) shPSAT1-up-regulated genes.
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B

Figure 41.

Suppression of PSAT1 results in reduced expression of genes across

the chr18p11 cytogenic band, which are partially rescued by re-expression of
PSAT1. A) The cartoon showing the map of down-regulated genes on chr18p11 cytogenic
bands. Highlighted genes with red color were tested with Real-Time PCR in B). N=4; *,
p≤0.05; ** p≤0.01; ***, p≤0.0001, and NS: not significant.
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Identification of PSAT1-associated genes differentially expressed in EGFR mutant NSCLC
PC9 cells have been frequently used as an in vitro model for EGFR mutant lung cancer
studies due to the presence of an activation mutation (exon19del) in the EGFR tyrosine kinase
domain and its responsiveness to EGFR tyrosine kinase inhibitor treatment (199). Within the above
transcriptomic analysis, RNA was collected from serum-starved PC9 cells to assess the EGFRdependent gene expression alterations while minimizing the contribution of other serum-factors
from the media. Therefore, we would expect to observe a subset of PSAT1-mediated genes that
have been independently implicated in EGFR-driven lung tumorigenesis. To identify these genes,
we designed a bioinformatic approach through a comparative analysis between the differentially
regulated genes in our RNA-seq analysis and publicly available microarray datasets obtained from
EGFR-mutant patient tumors.
GEO database (https://www.ncbi.nlm.nih.gov/geo/) stores a large number of microarray
datasets from various studies and makes them available for other researchers for their independent
investigations (169). We searched for gene expression datasets consisting of EGFR mutant lung
tumors and normal lung (n≥10, each) derived from untreated patients. Based on these criteria,
GSE31210, GSE31547, GSE31548, GSE27262, GSE32863, and GSE75037 were chosen for this
analysis. Clinical information on the EGFR mutant lung tumor samples and the microarray chip
platform were summarized in Table 7.
We utilized the BRB-ArrayTool, a user-friendly free software package for microarray data
analysis, to import the gene expression files of these datasets and perform statistical analysis to
determine PSAT1-associated genes in EGFR mutant tumors (151). The flow chart in Figure 42
demonstrates our strategy to determine these PSAT1-associated genes in EGFR mutant lung
tumors.
Briefly, the series matrix of each dataset, which includes the normalized value of gene
expression and the relevant clinical information, was imported by BRB ArrayTool “import data with
NCBI GEO series” plugins. After re-filtering, the PSAT1 associated DEG list from our RNA
sequencing study was used for a class comparison analysis between EGFR mutant lung tumor
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Table 7. The GEO microarray datasets harboring expression profiles from EGFR
mutant lung cancer and normal lung with relevant clinical information used in this study.

115

Figure 42. Strategic flow chart to identify PSAT1-associated genes from our PC9
study that are differentially expressed in human EGFR mutant lung tumors. ***, ID
number 31210, 27262, 31547, 31548, 32863, or 75037; FC, fold-change; T, tumor; N,
normal.
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and normal lung to determine the significantly altered genes. PSAT1-associated genes were
defined as those up-regulated in tumor tissues (T/N) that are correspondingly downregulated upon PSAT1 silencing in our RNA-seq profiling (shPSAT1-down-regulated) and,
conversely, down-regulated in tumor tissue (T/N) that are correspondingly up-regulated
upon PSAT1 loss (shPSAT1-up-regulated).
Gene lists derived from the GSE31547 and GSE31548 datasets were combined as
“GSE31547-48” since neither Affymetrix-HG-U133A nor Affymetrix-HG-U133B can cover all genes
from the RNA-seq list and expression profiles were obtained from the same patients (Table 7)
(200). We then compared the PSAT1-associated gene list from each dataset to obtain “common
genes” altered in all datasets using web tool: http://bioinformatics.psb.ugent.be/webtools/Venn/. As
some genes were represented by several probes, the number of probes was more than the number
of genes (Fig. 43A(i) and B(i)). Venn diagrams in Figure 43A(ii) and 43B(ii) highlight 13 genes from
our shPSAT1-down-regulated gene list and 12 genes from our shPSAT1-up-regulated genes list
from the RNA-seq study, respectively. These were classified as PSAT1-associated genes in
EGFR-mutant lung tumors as they were found to be differentially expressed in all the EGFR-mutant
lung cancer datasets (Fig. 43A(iii) and B(iii)).
To confirm these findings visually, the expression of these genes was extracted from each
dataset by BRB-ArrayTool. Cluster analysis was performed and heatmaps were generated by
dChIp software for each dataset. Figure 44 demonstrates that shPSAT1-down-regulated common
genes were increased in EGFR mutant tumors compared to normal tissue, while Figure 45 shows
shPSAT1-up-regulated common genes that were decreased in EGFR mutant tumor tissues.
Together, this bioinformatics approach was able to identify common genes linked through PSAT1
regulation in EGFR mutant lung tumors.
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(iii)

(i)

(ii)

(iii)

Figure 43. 13 shPSAT1-down-regulated and 12 shPSAT1-up-regulated genes are
defined as PSAT1-associated genes in EGFR mutant lung tumors. Selection of common
genes found across all EGFR-mutant tumor datasets that were A) shPSAT1-down-regulated
or B) shPSAT1-up-regulated in response to PSAT1 loss in our RNA-seq analysis.
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Figure 44. Heatmaps show increased expression of shPSAT1-down-regulated
common genes in EGFR-mutant tumor tissues compared to normal lung. T: Tumor and
N: Normal. Color key (Blue, Red)→(-2,2).
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Figure 45. Heatmaps show decreased expression of shPSAT1-up-regulated common
genes in EGFR-mutant tumor tissues compared to normal lung. T: Tumor and N:
Normal. Color key (Blue, Red)→(-2,2).
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A PSAT1-associated gene expression signature is associated with poor outcomes in
patients with EGFR mutant lung cancer
The combination of the down-regulated and up-regulated common genes collectively
identifies a PSAT1-associated gene signature for EGFR mutant lung cancer. We then wanted to
assess the relationship between this gene signature and both relapse-free and overall survival in
EGFR-mutant lung cancer patients. Among the datasets we used, GSE31210, GSE31547, and
GSE31548 contained patient survival information. However, we focused on GSE31210 dataset as
GSE31547 and GSE31548 had a limited number of EGFR mutant lung cancer samples (14 arrays)
for survival analysis and could not be combined due to the platform incompatibility.
Survival risk prediction tools from BRB-ArrayTool have been commonly used to test the
predictive ability of gene expression on patient outcomes (170, 201, 202). This tool calculates the
survival risk score from the sum of gene expression product and corresponding regression
coefficient for each gene. Based on this survival risk score, it assigns patients into two groups such
as “High Risk” and “Low Risk”: High Risk > mean (total survival risk score) > Low Risk. These
groups are then utilized to generate a Kaplan-Meier (KM) plot using patient survival information
and Receiver Operating Characteristic (ROC) curves. The KM plot demonstrates the predictive
ability of gene expression on patient outcomes, while the area under the curve (AUC) in the ROC
plot is accepted as the measure of predictive accuracy of the test and AUC above 0.7 is considered
significant (170, 203).
Unfortunately, we had only one dataset with survival information (GSE31210) on EGFRmutant NSCLC patients, so we were unable to validate our findings with another dataset. Therefore,
we performed overall survival and relapse-free survival analysis by the leave-one cross-validation
method with 100 permutation tests under principal component analysis with p ≤0.05 as previously
defined (170). 13 and 17 out of 25 genes were found to predict the overall survival and relapsefree survival rates, respectively (Fig. 46). In addition, 12 genes were observed in both overall
survival and relapse-free survival analyses.
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Figure 46. Common genes from the PSAT1-associated gene signature for EGFR
mutant lung cancer display predictive ability for both overall survival (OS) and
relapse-free survival (RFS).
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According to Kaplan-Meier Plot for overall survival, the high-risk group (defined by 13
genes out of 25) exhibited significantly shorter overall survival than the low-risk group (Fig. 47A(i)).
In addition, the prediction accuracy was supported by the AUC value (0.77) (Fig. 47A(ii)). Survival
risk prediction for relapse-free survival analysis found additional genes (17 genes out of 25) that
contributed to RFS. The KM plot demonstrated that the high-risk group correlated with worse
relapse-free survival (Fig. 47B(i)) with a prediction accuracy AUC value of 0.72 (Fig. 47(ii)). Taken
together, these results suggest that a PSAT1-associated gene signature is associated with poorer
outcomes in patients with EGFR-mutant NSCLC.
We then extracted the expression of these 25-genes in GSE31210 for cluster analysis and
subsequently heatmap generation. Figure 48 showed that the high-risk group identified by relapsefree survival analysis clustered together and exhibited the opposite expression profile of normal
lung. While the high-risk group comprised 21 of 24 stage II samples and 45 of 103 stage I patient
samples, the low-risk group derived from 58 stage I and only 3 stage II patient samples. Stage I
patients’ samples within the high-risk group displayed a similar expression pattern as the stage II
samples in the same group yet were different from the stage I patient samples within the low-risk
group. This implies that this PSAT1-associated gene signature for EGFR mutant lung cancer may
predict high-risk groups within stage I patients.
The probes and their corresponding genes involved in relapse-free and overall survival
prediction were summarized in Table 8 with their statistical significance (p-value) and contribution
to cross-validation (% CV support). We also added coefficients of each probe (wi) used in survival
risk score calculation. Probes/genes with positive coefficient indicate that higher expression is
correlated with shorter survival, whereas negative coefficient implies the higher expression is
associated with longer survival. Therefore, when looking at the sign of coefficients, we observed
that down-regulated genes upon PSAT1 silencing possessed positive coefficients and up-regulated
genes had negative coefficients, corroborating the findings above that PSAT1-associated gene
signature for EGFR mutant lung cancer is associated with poorer outcomes.
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(ii)

(i)
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Figure 47. PSAT1-associated genes for EGFR mutant lung cancer are found to be
associated with poorer clinical outcomes. (A-B) Cross-validated Kaplan-Meier Curve
and log-rank statistics based on permutation (i) and cross-validated ROC curve with AUC
value (ii) for A) overall survival analysis and B) relapse-free survival analysis in patients with
EGFR mutant lung cancer. ROC: Receiver Operating Characteristics; AUC: Area under
respective ROC curve.
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Figure 48. PSAT1-associated genes are able to discriminate a high-risk relapse group within stage I EGFR-mutant
lung cancer patients from the GSE31210 dataset. RFS: Relapse-free Survival. Color key (Blue, Red)→ (-2,2).

Table 8. Probe list of genes identified in the relapse-free survival and overall survival analysis of EGFR mutant patients’
samples. Shown are the Cox proportional hazards models (p≤0.05), %CV support: cross-validation, and Weight (wi): coefficient
of each probe used of survival risk score calculation.

Genes

Probe ID

CFD
FILIP1L

Relapse-Free Survival

Overall Survival

p-value

% CV Support

Weights (wi)

% CV Support

Weights (wi)

205382_s_at
1554965_at

2.055E-04
9.436E-03

100
100

-0.114579
-0.015713

100
96.85

-0.155391

GPRC5A

212444_at

5.962E-03

100

-0.069177

100

-0.097158

GPRC5A

235563_at

5.228E-03

100

-0.08264

98.43

-0.113706

HBEGF

244857_at

2.611E-04

100

-0.030123

100

-0.038612

MCM2

202107_s_at

5.760E-05

100

0.064114

100

0.090761

-0.019086

MMP15

243883_at

100

0.029494

PAICS

201013_s_at

6.360E-05

100

0.044286

100

0.059939

PSAT1

220892_s_at

4.256E-03

100

0.063036

98.43

0.088233

PSAT1

223062_s_at

1.716E-03

100

0.088942

92.91

0.121965

SCEL

1554921_a_at

1.656E-02

100

-0.070521

98.43

-0.107053

SCEL

232056_at

5.110E-03

100

-0.093097

100

-0.136887

SFN

209260_at

2.136E-04

100

0.054471

100

0.073341

SFN

33322_i_at

6.670E-05

100

0.034709

100

0.046443

SFN

33323_r_at

1.390E-03

100

0.040225

100

0.053199

SLC39A4

219215_s_at

1.350E-02

100

0.025303

98.43

0.037955

TYMS

1554696_s_at

8.194E-04

100

0.060664

100

0.083552

TYMS

202589_at

2.288E-03

100

0.086638

100

0.119874

UHRF1

225655_at

2.998E-02

96.85

0.103476

100

0.144022

CDCA7

224428_s_at

6.952E-03

100

0.070623

PAICS

201014_s_at

1.116E-03

100

0.048539

BTG2

201236_s_at

3.605E-02

96.06

-0.04939

203108_at

2.229E-02

100

-0.039503

NETO2

218888_s_at

2.223E-02

100

0.04869

NETO2

222774_s_at

4.979E-02

42.52

0.065235

JAG1

229924_s_at

2.418E-02

99.21

-0.024027

238439_at

2.015E-02

100

0.044862

GPRC5A

ANKRD22

1.139E-02
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EGFR mutant Tumor (n=127)

We performed a literature search for reported function and/or connection of our survival
genes in lung cancer and summarized these findings in Table 9. We observed that shPSAT1down-regulated genes (conversely increased in tumors) were associated with poor patient outcome
and tumor progression and involved in various oncogenic processes, including cell cycle
progression, proliferation, migration, and invasion. On the other hand, shPSAT1-up-regulated
genes (conversely decreased in tumors) have been linked to good prognosis and played roles in
inhibition of cell proliferation, migration, and invasion. Among these genes, BTG2 (B-cell
translocation gene 2) and GPRC5A (G Protein-Coupled Receptor Class C Group 5 Member A)
have already been accepted as tumor suppressors and GPRC5A acts as a negative regulator of
EGFR signaling in NSCLC cells (3, 32, 34). However, we were unable to find the relationship
between these genes and EGFR mutant lung tumors in the current literature, implying the novelty
of our PSAT1-associated genes in EGFR mutant lung cancer.
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Table 9. The role of genes found by relapse-free and overall survival analysis in NSCLC.
shPSAT1-down-regulated Genes (increased in tumors)
PSAT1
• Shorter overall survival in NSCLC (1, 2)
• Cell proliferation, cell cycle progression and tumor growth in vivo (1)
• Shedden_Lung_Cancer_Poor_Survival_A6 (4)
TYMS
• Associated with advanced stage, lymph node metastasis, and
vasculature invasion in lung adenocarcinoma (8)
• Shedden_Lung_Cancer_Poor_Survival_A6 (4)
SFN
• Increased expression in NSCLC by hypomethylation of promoter
and further reduced methylation with progression (10, 11)
• Early-stage lung adenocarcinoma marker for progression (12)
• Role in oncoprotein stabilization (13)
SLC39A4
• Associated with increased tumor size, regional lymph node
metastasis, and poor patient outcome (14)
• EMT
UHRF1
• Poor overall survival in lung adenocarcinoma(23)
• Role in regulation of epigenetic modulation during DNA duplication
in S-phase
• Hypomethylation of UHRF1-related genes
MMP15
• Associated with lymph node metastasis, tumor stage, and intratumoral microvessel density (24)
• EMT via degrading adherens and tight junction proteins (25)
NETO2
• Shorter overall survival in lung adenocarcinoma (26)
• Shedden_Lung_Cancer_Poor_Survival_A6 (4)
ANKRD22
• Relapse and shorter overall survival in NSCLC (27)
• Cell proliferation via increasing the expression of E2F1
MCM2
• Shorter overall survival and progression-free survival in lung
adenocarcinoma (29)
• Cell proliferation, cell cycle, and migration (30)
PAICS
• Disease progression and poor prognosis in lung adenocarcinoma
(31)
• De novo purine biosynthesis, cell proliferation, invasion, and
modulation of pyruvate kinase activity
• Shedden_Lung_Cancer_Poor_Survival_A6 (4)
CDCA7
• Shorter overall survival
• Involved in a variety of oncogenic processes (37)
(Continued)
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Table 9. Continued
shPSAT1-up-regulated genes (decreased in tumors)
BTG2
• Hypermethylation of promoter is associated with shorter overall
survival (3)
• Inhibition of cell proliferation and invasion and PI3K/AKT signaling
pathway
HBEGF
• Highly expressed in subgroup of lung cancer and associated with
advanced tumor growth (7)
• Patients with high serum level tend to longer progression-free and
overall survival (21)
JAG1
• Better overall survival rate (22)
CFD
NA
SCEL
• Shedden_Lung_Cancer_Good_Survival_A4 (4)
GPRC5A
• Low expression is associated with worse prognosis and advanced
TNM stage(32)
• Negative modulator of EGFR signaling in NSCLC cells and
inhibited by EGFR-dependent phosphorylation(33, 34)
• Shedden_Lung_Cancer_Good_Survival_A4 (4)
FILIP1L
• Down in lung cancer by DNA methylation (35)
• Inhibition of cell migration
• Reduced nuclear β-catenin expression (36)
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PSAT1-associated gene signature is unable to predict the risk groups in other NSCLC
tumors
In addition to EGFR-mutant lung tumors, the GSE31210 microarray dataset also harbors
ALK-fusion positive, KRAS mutant, and EGFR/KRAS/ALK wild-type tumor samples with their
corresponding clinical information. Therefore, we investigated whether the predictive ability of
PSAT1-associated gene signature is specific to EGFR mutant lung cancer or applies to NSCLC
tumors with other oncogenic drivers. Therefore, we performed survival risk prediction analysis for
KRAS mutant and EGFR/KRAS/ALK wild-type tumors as described above. Survival analysis for
ALK-fusion positive only tumors was excluded due to the limited sample size (n=10).
EGFR/KRAS/ALK wild-type tumors were identified as EGFR/KRAS wild-type so as to not lead to
confusion.
Expression profiles of JAG1, BTG2, ANKRD22, GPRC5A, and ALOX5 genes in KRAS
mutant tumor and ALOX5 expression in EGFR/KRAS wild-type tumor resulted in the Kaplan-Meier
overall survival curve construction (Fig. 49A and C, respectively). However, these genes were
unable to separate the high-risk groups from the low-risk groups in neither KRAS mutant tumor nor
EGFR/KRAS wild-type tumor. Kaplan-Meier relapse-free survival curves were generated from the
expression profile of SCEL, MMP15, JAG1, BTG2, and ANKRD22 in KRAS mutant tumor and
PSAT1 and SFN in EGFR/KRAS wild-type tumor (Fig. 49B and D, respectively). Although we
observed better separation between high-risk and low-risk groups for the relapse-free survival
curve in both KRAS mutant and EGFR/KRAS wild-type tumors compared with overall survival
curves, they did not reach statistical significance.
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A

B

C

D

Figure 49. Survival risk predictions with the identified PSAT1-associated genes
from EGFR mutant lung cancer against other NSCLC tumors. (A-D) Cross-validated
Kaplan-Meier Curve and log-rank statistics based on permutation for overall survival
analysis in patient with A) KRAS mutant and C) EGFR/KRAS wild-type tumor and B)
relapse-free survival analysis in patients with KRAS mutant and D) EGFR/KRAS wildtype tumor.
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Identification of potential PSAT1-associated metastatic gene signature
The PSAT1-associated gene signature we have described is mainly dominated by earlystage EGFR mutant lung cancer transcriptomic profiles due to the presence of a high number of
stage I patients in GSE31210 (N=103) and GSE27262 (all stage I tumors). These datasets may
inform us to the relevance of this PSAT1-associated gene signature for EGFR tumor initiation and
early progression, but at the same time, these may hamper the identification of potential PSAT1associated genes involved in late-stage tumor progression and metastasis as these microarray
datasets had a limited number of stage-III and even fewer stage IV samples. Therefore, we decided
to analyze the GSE14107 microarray dataset, which encompasses transcriptomic profiles of the
PC9-parental line and the PC9-BrM3 brain metastatic sublines (172).
We hypothesized that PSAT1-associated metastatic genes would be upregulated in PC9BrM3 and correlate with down-regulated genes in our PSAT1 silencing RNA-seq results and vice
versa. To identify these genes, the GSE14107 microarray dataset was retrieved by BRB-ArrayTool
as described before. Then, differentially expressed genes between PC9 and PC9-BrM3 cells were
determined by class comparison plugin based on the same criteria used before: 1.4 fold- change
and p≤0.05. Common genes between groups were determined by Venn diagram drawing webtool
(http://bioinformatics.psb.ugent.be/webtools/Venn/).
As shown in Figures 50A and B, 51 genes from the sh-PSAT1-down-regulated gene list
and 30 genes from the shPSAT1-up-regulated gene list were identified as potential PSAT1associated metastatic genes. To confirm these findings visually, we extracted the differential
expression profile of these genes between PC9-P and PC9-BrM3 cells from GSE14107. After
performing cluster analysis, heatmaps were generated by dChIP. Figures 50C and D, respectively,
demonstrated the up-regulation of genes in PC9-BrM3 from the shPSAT1-down-regulated gene list
and down-regulation of genes in PC9-BrM3 from the shPSAT1-up-regulated gene list. Interestingly,
PSAT1 was one of the genes that increased in PC9-BrM3 cells, further supporting our hypothesis
that these genes may contribute to PSAT1’s metastatic potential in PC9 cells.
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A

B

D

C

Figure 50. Potential PSAT1-associated metastatic genes are obtained from the
differentially expressed genes between PC9-parental and PC9-BrM3 sublines. (A-B)
Venn diagram displaying the number common genes in A) shPSAT1-down-regulated list
and B) shPSAT1-up-regulated list. (C-D) Heatmaps displaying the expression profile of
the common genes identified from C) Venn diagram in A and D) Venn diagram in B. Color
key (Blue, Red)→(-2,2).
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Discussion
PSAT1 expression is elevated in many types of cancer, including NSCLC and associated
with poor patient outcomes (1, 2, 44). While its metabolic function within SSP activity contributes
to cell proliferation and tumor growth, oncogenic signals may promote alternative functions that
may promote tumor progression; particularly as nuclear localization of PSAT1 in EGFR-activated
lung cancer cells was observed in our study. To gain better insight into the role of PSAT1 in
tumorigenesis and identify potential alternative activities, genome-wide expression profiling by
RNA-seq technology was performed. Differentially expressed genes were intensely interrogated
using bioinformatics tools for comparisons with other gene expression datasets.
Inhibition of serine biosynthetic pathway impacts several metabolic pathways, including
folate, glutathione, and nucleotide biosynthesis (Fig. 2) (15, 20, 40, 45). PSAT1 silencing led to
down-regulation of genes involved in these pathways and reduced anchorage-independent growth,
which was partially restored by downstream metabolites supplementation. These findings support
a metabolic function for PSAT1 within the serine biosynthetic pathway. PSAT1 is also implicated in
the inhibition of GSK3β dependent phosphorylation and proteasomal degradation of target proteins
(Fig. 5)(1, 43, 69).

In addition, PSAT1-mediated stabilization of cyclin D1 promotes E2F

transactivation in NSCLC cells and consistent with this finding, loss of PSAT1 was found to reduce
the expression of E2F target genes (1). β-catenin was another potential target for PSAT1/GSK3β
pathway and implicated in EGFR-mutant lung tumorigenesis (43, 176, 178). Although our gene
expression analysis was unable to demonstrate how PSAT1 loss alters β-catenin transactivation,
reduction in the total and nuclear β-catenin level and luciferase activity corroborates these previous
findings that PSAT1 may be involved in the regulation of β-catenin stability. Taken together, these
suggest that PSAT1 loss mediated gene expression changes support known tumorigenic functions
of PSAT1.
Loss of PSAT1 severely affects the cell motility of EGFR-activated cells, as shown in
Chapter 2. Through exploring gene expression alterations involved in cell migration, we observed
down-regulation of genes involved in actin cytoskeleton arrangement in PSAT1 silenced cells.
Among these genes, expressions of FHOD1, TMSBX4, and S100A4, which are well-known actin-
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associated proteins involved in actin fiber formation and cell migration, were assessed and
validated as the downstream targets of PSAT1. However, their role in PSAT1-mediated cell
migration requires further investigation.
Nuclear localized metabolic enzymes, including PDC, ACLY, α-KGDH, are involved in
epigenetic regulation via providing substrate for histone modifications (122, 124, 127). Accordingly,
finding nuclear PSAT1 in EGFR activated lung cancer cells and previous reports showing the
involvement of PSAT1 in epigenetic regulation prompted us to explore the differentially regulated
genes located within certain chromosomal regions (46, 136).

Twenty-nine genes located in

Chr18p11 were found to be down-regulated upon PSAT1 silencing. Real-time PCR analysis of
seven out of eight genes verified as PSAT1 down-stream targets, implying a putative long-range
gene expression regulation by PSAT1 within this genetic locus. Further investigation is also
required to elucidate any involvement of PSAT1-mediated epigenetic regulation in this region.
Availability of gene expression datasets from EGFR mutant lung cancer and the use of
publicly available bioinformatics software for expression analysis provided us the opportunity to
examine the clinical significance of a PSAT1-associated gene signature. We found twenty-five
PSAT1 associated genes linked to EGFR-mutant lung cancer from the analysis of six different
patient-derived datasets. Survival prediction analysis found that a subset of genes within this list
significantly predicts overall and relapse-free survival in EGFR-mutant NSCLC patients. Consistent
with this, the expression pattern of these genes in the stage I high-risk group is similar to that
observed in the stage II high-risk group. On the other hand, this signature fails to predict other
NSCLC types of tumors' patient outcomes. However, at this time, the limited number of KRAS
mutant tumors analyzed precludes us from making a definitive conclusion that this signature is
specific to EGFR mutant tumors.
As early-stage cancers dominate the gene signature obtained from human EGFR mutant
lung tumors, analysis of genes involved in late-stage tumor progression and metastasis is limited.
Therefore, differentially expressed genes between parental PC9-P and brain metastatic PC9-BrM3
were extracted from the Nguyen et al. study (172). Comparative analysis with RNA-seq data found
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that 18.2 % of shPSAT1-down-regulated and 14.2% of shPSAT1-upregulated genes displayed the
same pattern between metastatic versus parental PC9 cells and were defined as a potential
PSAT1-associated metastatic gene signature. PSAT1 and PSAT1-mediated actin-related proteins,
including S100A4, SMTN, and CALB2, were found within this list, supporting the notion that PSAT1
contributes to cell motility via regulating the actin cytoskeleton. Thus, these findings suggest the
putative involvement of PSAT1 in the metastasis of EGFR mutant lung cancer.
In summary, these studies examined genome-wide expression changes upon PSAT1
silencing using gene profiling and bioinformatics approaches. Our analysis corroborated previous
findings on the role of PSAT1 within the serine biosynthetic pathway in regulating E2F activity and
β-catenin protein expression/transcription activity. We also validated PSAT1’s impact on actinrelated genes as F-actin stress fiber formation was restored by re-expression of PSAT1.
Comparative analysis of our genomic profiling against public gene expression data yielded a
PSAT1-associated gene signature with prognostic value in EGFR-mutant NSCLC patient
outcomes.
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CHAPTER 4
CONCLUSION & FUTURE STUDIES
Investigation into the oncogenic function of PSAT1 has been relatively limited to general
phenotype analysis in response to silencing or ectopic expression in tumor cells. Therefore, the
complete mechanism(s) for the tumor-promoting activity of PSAT1 remains elusive. Through
biochemical and genomic approaches, this work highlights a novel function for PSAT1 in EGFRmediated lung tumorigenesis.
Results supportive of a non-canonical function of PSAT1
In this study, we initially assessed PSAT1’s metabolic contribution to cell migration through
metabolite rescue upon PSAT1 loss. Separately, we also compared PSAT1’s cell motility effects to
those caused by PHGDH silencing. We found that metabolite supplementation failed to rescue the
migration defect due to PSAT1 suppression and loss of PHGDH significantly impacted cell motility
to a lesser extent than PSAT1 depletion (Chapter 5, Fig. 55). More notably, unlike PSAT1 silencing,
depletion of PHGDH did not affect nuclear PKM2 translocation (Chapter 5, Fig. 54). Taken together,
we postulate that PSAT1 differentially contributes to EGFR-mutant lung cancer cell motility through
a non-canonical function, potentially facilitating nuclear PKM2 localization and activity.

EGFR mutant lung cancer preferentially metastasizes to the brain and bone (204-207).
Due to the blood-brain barrier, serine biosynthesis in neuronal cells is crucial and targeting SSP
activity could have detrimental side effects (15). Our bioinformatic analysis indicated elevated
PSAT1 expression in a brain-metastatic subline (PC9-BrM3) of EGFR-mutant NSCLC. Further, our
findings suggest that other activities beyond PSAT1’s metabolic activity may be required for cell
migration. Therefore, it is crucial to elucidate any non-canonical function(s) of PSAT1 in cell
migration and the metastatic potential of PC-BrM3 cells. Targeting these PSAT1 functions may
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prove to be a therapeutic option to suppress brain metastasis in EGFR-mutant lung cancer
patients.

Potential mechanisms by which nuclear PSAT1 may mediate gene regulation
This study has demonstrated that the EGFR signaling facilitates the nuclear localization of
PSAT1. Nuclear localization of PSAT1 appears independent of PKM2 function (Chapter 2, Fig. 15)
and elucidating the mechanism(s) which facilitate PSAT1 translocation is currently ongoing. Yet,
we propose a model by which PSAT1 may exert its nuclear activity (Fig. 51).
Catalytic-dependent pathway
Similar to PSAT1, we also observed activated EGFR-dependent nuclear localization of
PHGDH (Chapter 5, Fig.54). As both SSP enzymes are driven to the same cellular compartment,
we speculate that nuclear PHGHD and PSAT1 catalytic activity may influence the cellular
epigenetic landscape by producing key metabolites required for epigenetic modifiers (Fig. 51A).
Specifically, α-KG serves as a substrate for both the Jumonji C domain containing lysine
demethylases (KDM2-7) and ten-eleven translocation hydroxylases (TET1-3) that mediate histone
and DNA demethylation, respectively (204). In support of this, epigenetic regulation by PSAT1derived α-KG is required for the pluripotency of mouse embryonic stem cells (136). Thus, we
postulate that nuclear α-KG production through concerted PHGDH and PSAT1 activity leads to
hypomethylation of DNA and histones. While less likely, alternatively, nuclear PHGDH could
metabolize α-KG for the production of the oncometabolite 2-HG. As 2-HG competitively inhibits the
KDM and TET enzymes, this would lead to histone and DNA hypermethylation. Although PHGDH
derived 2-HG has been reported in breast cancer cells, it is still unclear whether the level of 2-HG
produced is sufficient to impact the epigenetic landscape in these cells (135). As described in
chapter 1, there are several examples of metabolic enzymes contributing to histone modifications
due to nuclear localization and local substrate production (122, 126, 127); therefore, it is plausible
that nuclear-localized PHGDH and PSAT1 may act to produce metabolites that impact the
epigenetic landscape in these lung cancer cells. This potentially would lead to differential gene
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expression across a large chromosomal area, similar to what we observed for the 18p11
cytogenetic locus.
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Figure 51. Schematic representation of putative nuclear PSAT1 function(s) in EGFRactivated cells. A) Catalytic-dependent nuclear PSAT1 function. Increased α-KG
production may lead to both histone and DNA hypomethylation via activation of enzymes:
KDM and TET. Conversely, PHGDH-mediated 2-HG production that would inhibit these αKG-dependent enzymes and result in hypermethylation B) Catalytic-independent nuclear
PSAT1 function. PSAT1 contributes to gene regulation through interaction with other
transcription factors (TF) or nuclear PKM2. KDM: Lysine demethylase; TET: ten–eleven
translocation hydroxylases.
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Catalytic-independent pathway
PSAT1 may also exert a nuclear function as part of a transcriptional complex, similar to
that reported with PKM2 and β-catenin (Fig. 51B)(113). As both PSAT1 and PKM2 localize to the
nucleus in EGFR-activated cells, we can question whether nuclear PSAT1 may influence gene
expression via interacting with PKM2.
In short, our findings demonstrate the nuclear localization of PSAT1 in both

EGF-

stimulated EGFR-WT A549 and EGFR-mutant PC9 NSCLC cell lines, but elucidation of its nuclear
function as it relates to tumor progression requires further investigation. Our initial future plans are
to generate cells expressing PSAT1 catalytically inactive and/or nuclear localization deficient
mutants to explore effects on nuclear metabolism, histone modifications, and interacting proteins
within the nucleus. The differentially expressed genes from the RNA-seq data (Chapter 3) can
serve as read-outs to delineate the metabolic vs. non-metabolic and cytosolic vs. nuclear function
of PSAT1 in gene regulation. For example, UHRF1 (Ubiquitin-like, with PHD And Ring finger
domains 1) is one of the EGFR linked PSAT1 associated genes, which is down-regulated upon
PSAT1 silencing. UHRF1 functions as an epigenome adaptor protein that can recognize hemimethylated DNA and methylated histones to recruit DNA methyltransferase 1 and histone
methyltransferase (205, 206). Several reports demonstrated the involvement of UHRF1 in silencing
tumor suppressor genes by DNA hypermethylation. FILIP1L (Filamin A interacting protein 1 like)
and BTG2 within the shPSAT1-upregulated gene list act as tumor suppressors and are decreased
in lung tumors by promoter hypermethylation (3, 35, 36). Thus, we can ask whether UHFR1 plays
a role in PSAT1-mediated epigenetic regulation and whether the upregulation of these tumor
suppressor genes is a result of DNA hypomethylation through using DNA immunoprecipitation
(DIP)-PCR or DIP-seq analysis.
A potential role for PSAT1 in immune modulation through regulating the protein secretory
pathway
We have so far focused on the intrinsic oncogenic function(s) of PSAT1 in EGFR-activated
NSCLC and demonstrated its effects on anchorage-independent growth, cell migration, and actin
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cytoskeleton rearrangements. However, GO analysis of the transcriptomic data in Chapter 3 also
suggest a potential extrinsic function for PSAT1.
According to GO_BP analysis, genes involved in immune response and leukocyte
migration/chemotaxis were upregulated upon PSAT1 silencing (Chapter 3, Table 5). In addition,
exocytosis, endocytosis, and secretion are other biological processes observed to be regulated by
PSAT1 and tumor cells routinely utilize these mechanisms to modulate the tumor microenvironment
(207, 208). The cellular component analysis found up-regulated genes whose protein products are
localized in the Golgi, within the membrane and lumen of vesicles, and within secretory
membranes, suggesting a change in vesicle-mediated transport and secretion. While it is hard to
determine the extrinsic activity of PSAT1 by analyzing intrinsic transcriptomic profiles, these studies
suggest, at the least, that loss of PSAT1 may alter the secretory pathway in tumor cells.

Immunotherapy yields promising results if it is applicable to the patients. Immune
checkpoint inhibitors (ICI) have become the part of the therapy for NSCLC patients, but EGFR
mutant lung cancer patients are excluded from this treatment since EGFR mutant patients have
limited responses to ICI treatment (209). Thus, it is intriguing to investigate how tumoral PSAT1
may modulate the tumor microenvironment and whether targeting PSAT1 activity may sensitize
EGFR mutant lung tumors to ICI treatment.

Potential role in resistance to EGFR-TKI therapies

Although patients with EGFR-activating mutations exhibit clinical responses to EGFR-TKI
treatments, the development of resistance typically occurs within a year (98). A secondary mutation
at T750M accounts for 50% of these cases. Mutations in genes involved in downstream pathways
or activation of other RTKs represent other potential mechanisms that cause recurrence. Therefore,
targeting resistance mechanisms within EGFR signaling underscores the rationale for current
combination therapy research.

Recently, targeting metabolic pathways has become a strategy in combination therapies.
Dong et al. demonstrated that PHGDH was upregulated in erlotinib resistance cells and inhibition
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of activity via either inhibitor or silencing induces sensitivity (47). Another study supports this via
ectopic expression of PSAT1 in EGFR mutant HCC827 NSCLC cells, which induced resistance to
EGFR-TKI treatment (210). A xenograft study with EGFR mutant lung cancer cells demonstrated
that combination therapy with a glutaminase (GLS) inhibitor enhances the anti-tumor activity of
erlotinib (102). Therefore, it is intriguing whether targeting PSAT1 function together with EGFR-TKI
improves patients’ outcomes as PSAT1 is the connection between both serine synthesis and
glutaminolysis.

Findings that yield new questions
•

PKM2 was identified as a PSAT1-associating protein in NSCLC cells and required PSAT1
expression for translocation into the nucleus upon EGFR activation. Interestingly, it is still
unclear whether this interaction is completely responsible for the nuclear localization of
PKM2. Separately, loss of PSAT1 could impact EGFR signaling, including ERK, that is
involved in mediating PKM2 nuclear localization. GPRCA5 is upregulated upon PSAT1
loss and is associated with a better overall and relapse-free survival rate of EGFR mutant
lung cancer. A previous study reported that loss of GPRCA5 expression was associated
with poor patient outcomes in NSCLC, as it functions as a tumor suppressor in lung
tumorigenesis (32). Loss of GPRCA5 expression promotes EGFR signaling activation,
which is lost by GPRCA5 restoration (34). Therefore, we speculate that PSAT1 may
promote EGFR signaling via suppressing GPRC5A expression.

•

Nuclear PKM2 is required for EGFR-induced β-catenin transactivation of target genes
involved in cell proliferation, the Warburg effect, and cell invasion in various tumor cell
types (113, 158). In our experimental settings, loss of PSAT1 led to decreased β-catenin
expression and nuclear PKM2 localization. Nuclear acetyl-mimetic PKM2 re-expression
failed to restore β-catenin expression in PSAT1-depleted cells, indicating that regulation of
β-catenin expression is independent of nuclear PKM2 function. As the restoration of
nuclear PKM2 partially rescued the migration defect due to PSAT1 loss, it is intriguing
whether reduced β-catenin expression separately impacts cell motility.
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•

Co-IP analysis with recombinant proteins demonstrated the direct interaction between
PSAT1 and PKM2, but not PKM1 (Chapter 2). Furthermore, we found that the pyruvate
kinase activity of recombinant PKM2, but not PKM1, increases in the presence of active
PSAT1 (Chapter 5, Fig. 52). PSAT1 further induces recPKM2 activity in the presence of
allosteric activators: fructose 1,6-bisphosphate (FBP) and serine (Chapter 5, Fig. 53).
These results indicate that PSAT1 has a functional consequence on PKM2 activity, at least
under these conditions. However, loss of PSAT1 did not lead to reduced cellular pyruvate
kinase activity in two NSCLC cell types. This could be due to saturating conditions of PKM2
allosteric regulators and maybe context-dependent or environment-specific (i.e., limiting
nutrient conditions). It should also be noted that the activity of PSAT1 was not assessed in
the presence of PKM2. It is possible that PSAT1 activity may also be affected by PKM2,
as PSAT1 could be a protein substrate for PKM2’s protein kinase activity.

Summary
In this dissertation, I investigated a pro-tumorigenic function for PSAT1 that may be beyond
its activity within the serine biosynthetic pathway. For this, I employed two independent discovery
methodologies: identification of PSAT1 interacting proteins by GST-pull down coupled MS analysis
and RNA-seq profiling. PSAT1 interacts with PKM2 and induces recombinant PKM2 pyruvate
kinase activity in vitro, but the disruption of this interaction by PSAT1 silencing does not impact the
cellular pyruvate kinase activity in NSCLC cells. Yet, PSAT1 is required for the EGFR-mediated
nuclear localization of PKM2.
PSAT1 loss impairs anchorage-independent growth and cell migration in EGFR-mutant
NSCLC cells. Mechanistic studies using a variety of rescue experiments demonstrated that
anchorage-independent growth requires the metabolic function of PSAT1 but not nuclear PKM2
activity. On the other hand, nuclear PKM2 contributes to PSAT1-mediated cell migration in EGFRactivated cells. Although my results suggest the involvement of a non-canonical function for PSAT1
in cell migration, rescue studies using a catalytically inactive, localization-dependent PSAT1 mutant
are currently ongoing to unravel the full mechanism.
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RNA-seq analysis corroborates the phenotypic analysis of PSAT1 loss and provides
molecular insight about genomic changes that are regulated by PSAT1. For example, I found
differential expression of genes involved in actin cytoskeleton rearrangement that have defined
impacts on cell migration, which was confirmed by alterations in F-actin formation. Lastly, I
identified a PSAT1-dependent gene signature that had prognostic value for patient outcomes in
EGFR-mutant NSCLC.
In conclusion, I postulate that PSAT1 has a novel function that contributes to EGFRmediated lung tumorigenesis beyond its metabolic activity in SSP. Our findings in this study will
guide us as we continue to dissect the contribution of both the canonical and/or non-canonical
functions of PSAT1 involved in promoting EGFR-mutant NSCLC.
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CHAPTER 5
EXTENDED RESULTS DISCUSSED IN CHAPTER 4
Recombinant PSAT1 enhances pyruvate kinase activity of recombinant PKM2
Our proteomic study revealed an interaction between PSAT1 and PKM2 (Chapter 2); yet
a functional role for this interaction on enzymatic activity was unknown. In this small study, we
investigated the consequence of recombinant (rec-)PSAT1 on the pyruvate kinase activity of recPKM2. We also tested whether rec-PSAT1 would influence the known effects of rec-PKM2
allosteric activators. We modeled our study according to the protocol described in Chaneton et al.
(57). We found that rec-PKM2 activity in vitro increased in a dose-dependent manner in response
to rec-PSAT1 concentrations and that heat-inactivation abrogated this effect (Fig. 52). As we have
demonstrated that rec-PSAT1 selectively associates with rec-PKM2, the presence of rec-PSAT1
had no effect on rec-PKM1 activity (Fig. 52). Therefore, this result indicates that PSAT1 can induce
PKM2, at least in this in vitro cell-free system.
To further examine rec-PSAT1’s influence on rec-PKM2, we determined the pyruvate
kinase activity of rec-PKM2 in the presence of allosteric activators, such as fructose-1,6bisphosphate (FBP) or serine, in response to different concentrations of rec-PSAT1. We found that
the addition of rec-PSAT1 can further activate rec-PKM2 in the presence of the known activator
FBP (Fig. 53A). In addition, rec-PSAT1 also stimulated rec-PKM2 in the presence of serine (Fig.
53B). In short, these results demonstrate that rec-PSAT1 induction is specific to rec-PKM2 in vitro
and may differently regulate rec-PKM2 compared to other known allosteric activators.

146

Figure 52. rec-PSAT1 induces the pyruvate kinase activity of rec-PKM2 but not recPKM1. Pyruvate kinase activity was assessed by quantifying levels of ATP using
luminescent Kinase-Glo reagent (Promega) after addition of either rec-PKM2 or recPKM1 in the presence of increasing concentrations of rec-PSAT1. To verify requirement
for active rec-PSAT1, the protein was inactivated via boiling for 10 minutes prior to
addition to the in vitro reaction.
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Figure 53. rec-PSAT1 further induces rec-PKM2 activity in the presence of allosteric
activators. Rec-PKM2’s pyruvate kinase activity was followed by quantifying levels of
ATP using luminescent Kinase-Glo reagent (Promega) in the presence of A) FBP or B)
serine and increasing concentrations of rec-PSAT1. Rec-PKM2 activity in the presence of
the allosteric activator but in the absence of rec-PSAT1 was set to 1. * , p≤ 0.05

148

Loss of PHGDH does not impact the nuclear localization of PKM2
As shown in chapter 2, PSAT1 is required for EGFR-mediated PKM2 nuclear localization.
We then questioned whether other SSP enzymes may also be involved in this regulation. PHGDH,
the rate-limiting enzyme, was stably silenced in PC9 cells and cell fractionation was performed to
examine protein localization. Unlike PSAT1, loss of PHGDH did not affect the nuclear localization
of PKM2 (Fig. 54). However, we also observed the nuclear localization of PHGDH that is dependent
on EGFR-signaling. This implies that there may be a nuclear requirement for SSP activity in EGFR
activated NSCLC.
Next, we performed wound-healing assays to assess the effect of PHGDH loss in cell
migration. We found that PHGDH depletion resulted in only a slight reduction in cell migration,
which was considerably less than that observed with PSAT1 loss (Fig. 55). Taken together, these
results suggest that inhibition of serine biosynthesis via PHGDH depletion may not fully recapitulate
the loss of PSAT1 phenotype in EGFR-mediated PKM2 nuclear localization and cell migration,
potentially due to PSAT1’s selective requirement for PKM2 nuclear translocation.
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Figure 54. Loss of PHGDH does not affect the nuclear localization of PKM2 in PC9
cells. EGFR-mutant PC9 cells stably expressing Control or PHGDH shRNA were treated
with 1 µM of erlotinib for 48 hrs. Cytoplasmic and nuclear fractions were examined by
immunoblot analysis using anti-PKM2 and anti-PHGDH antibodies. OCT1 and α-tubulin
served as loading controls for nuclear and cytoplasmic compartments, respectively. Shown
are representative images from three separate experiments.
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Figure 55. Cell migration is slightly affected upon PHGDH depletion in PC9 cells.
Wound healing assay of serum-starved PC9 cells expressing Control or PHGDH-specific
shRNA. Representative images at 0 hr and 24 hr with migrating cells demarcated by white
continuous lines. Data is presented as migrated area after 24 hours and shown is mean ±
SE from three independent experiments. * p < 0.005.
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